AU3563499A - Transfection of male germ cells for generation of selectable transgenic stem cells - Google Patents
Transfection of male germ cells for generation of selectable transgenic stem cells Download PDFInfo
- Publication number
- AU3563499A AU3563499A AU35634/99A AU3563499A AU3563499A AU 3563499 A AU3563499 A AU 3563499A AU 35634/99 A AU35634/99 A AU 35634/99A AU 3563499 A AU3563499 A AU 3563499A AU 3563499 A AU3563499 A AU 3563499A
- Authority
- AU
- Australia
- Prior art keywords
- stem cell
- vertebrate
- cell
- transgenic
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 191
- 230000009261 transgenic effect Effects 0.000 title claims description 153
- 238000001890 transfection Methods 0.000 title claims description 50
- 210000003794 male germ cell Anatomy 0.000 title claims description 35
- 210000004027 cell Anatomy 0.000 claims description 242
- 238000000034 method Methods 0.000 claims description 170
- 102000016736 Cyclin Human genes 0.000 claims description 160
- 108050006400 Cyclin Proteins 0.000 claims description 160
- 108090000623 proteins and genes Proteins 0.000 claims description 138
- 210000004602 germ cell Anatomy 0.000 claims description 92
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 83
- 241000282414 Homo sapiens Species 0.000 claims description 75
- 230000014509 gene expression Effects 0.000 claims description 75
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 61
- 238000000338 in vitro Methods 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 45
- 230000002103 transcriptional effect Effects 0.000 claims description 43
- 238000001727 in vivo Methods 0.000 claims description 41
- 230000027455 binding Effects 0.000 claims description 39
- 230000011987 methylation Effects 0.000 claims description 39
- 238000007069 methylation reaction Methods 0.000 claims description 39
- 102000040430 polynucleotide Human genes 0.000 claims description 37
- 108091033319 polynucleotide Proteins 0.000 claims description 37
- 239000002157 polynucleotide Substances 0.000 claims description 37
- 239000005089 Luciferase Substances 0.000 claims description 35
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 108060001084 Luciferase Proteins 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 239000012212 insulator Substances 0.000 claims description 26
- 238000001476 gene delivery Methods 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 19
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 18
- 239000005090 green fluorescent protein Substances 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 18
- 241000894007 species Species 0.000 claims description 18
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 claims description 17
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 16
- 238000009395 breeding Methods 0.000 claims description 16
- 230000001488 breeding effect Effects 0.000 claims description 16
- 241000287828 Gallus gallus Species 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 14
- 210000003734 kidney Anatomy 0.000 claims description 13
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 12
- 108060006184 phycobiliprotein Proteins 0.000 claims description 12
- 229920000656 polylysine Polymers 0.000 claims description 12
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 12
- 102000002554 Cyclin A Human genes 0.000 claims description 11
- 108010068192 Cyclin A Proteins 0.000 claims description 11
- 230000004720 fertilization Effects 0.000 claims description 11
- 230000007067 DNA methylation Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 210000002149 gonad Anatomy 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 210000004681 ovum Anatomy 0.000 claims description 9
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- 101000915402 Homo sapiens Deleted in azoospermia protein 1 Proteins 0.000 claims description 8
- 241000286209 Phasianidae Species 0.000 claims description 8
- 241000700159 Rattus Species 0.000 claims description 8
- 108010041089 apoaequorin Proteins 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 230000003394 haemopoietic effect Effects 0.000 claims description 8
- 102000055460 human DAZ1 Human genes 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 241000282465 Canis Species 0.000 claims description 7
- 241000283153 Cetacea Species 0.000 claims description 7
- 241000699800 Cricetinae Species 0.000 claims description 7
- 241000282324 Felis Species 0.000 claims description 7
- 241000699694 Gerbillinae Species 0.000 claims description 7
- 241000272458 Numididae Species 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 230000000747 cardiac effect Effects 0.000 claims description 7
- 210000004420 female germ cell Anatomy 0.000 claims description 7
- 230000000788 granulopoietic effect Effects 0.000 claims description 7
- 210000000933 neural crest Anatomy 0.000 claims description 7
- 230000001537 neural effect Effects 0.000 claims description 7
- 230000002188 osteogenic effect Effects 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 230000002782 sympathoadrenal effect Effects 0.000 claims description 7
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 6
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 6
- 102000015215 Stem Cell Factor Human genes 0.000 claims description 5
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 claims description 4
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 claims description 4
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 claims description 4
- 102100034670 Myb-related protein B Human genes 0.000 claims description 4
- 101710115153 Myb-related protein B Proteins 0.000 claims description 4
- 101150042435 Xrcc1 gene Proteins 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 241000272525 Anas platyrhynchos Species 0.000 claims 6
- 241000272814 Anser sp. Species 0.000 claims 6
- 241000271571 Dromaius novaehollandiae Species 0.000 claims 6
- 241000283073 Equus caballus Species 0.000 claims 6
- 241000272534 Struthio camelus Species 0.000 claims 6
- 241000282898 Sus scrofa Species 0.000 claims 6
- 230000036760 body temperature Effects 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 description 98
- 241001465754 Metazoa Species 0.000 description 86
- 108020004414 DNA Proteins 0.000 description 73
- 210000001550 testis Anatomy 0.000 description 55
- 210000001519 tissue Anatomy 0.000 description 38
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 35
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 35
- 230000035772 mutation Effects 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000022131 cell cycle Effects 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 108091034117 Oligonucleotide Proteins 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 238000011144 upstream manufacturing Methods 0.000 description 19
- 108700008625 Reporter Genes Proteins 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 230000002381 testicular Effects 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- 108010060273 Cyclin A2 Proteins 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 238000011830 transgenic mouse model Methods 0.000 description 15
- 210000005239 tubule Anatomy 0.000 description 15
- 102000008162 Cyclin A2 Human genes 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 14
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 210000002863 seminiferous tubule Anatomy 0.000 description 12
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000022983 regulation of cell cycle Effects 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 230000021595 spermatogenesis Effects 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 108700009124 Transcription Initiation Site Proteins 0.000 description 10
- 102000040945 Transcription factor Human genes 0.000 description 10
- 108091023040 Transcription factor Proteins 0.000 description 10
- 101150115889 al gene Proteins 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000000066 myeloid cell Anatomy 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108091029523 CpG island Proteins 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 230000027311 M phase Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000018199 S phase Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 7
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001351 cycling effect Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000030279 gene silencing Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108091007914 CDKs Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000012239 gene modification Methods 0.000 description 6
- 230000005017 genetic modification Effects 0.000 description 6
- 235000013617 genetically modified food Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 108010053210 Phycocyanin Proteins 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 230000013011 mating Effects 0.000 description 5
- 210000001178 neural stem cell Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000934320 Homo sapiens Cyclin-A2 Proteins 0.000 description 4
- 101710147844 Myb protein Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000001369 bisulfite sequencing Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000009027 insemination Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000037426 transcriptional repression Effects 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 3
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000021121 meiosis Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000010765 pachytene Effects 0.000 description 3
- 210000000557 podocyte Anatomy 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002830 rete testis Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000717 sertoli cell Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000001325 yolk sac Anatomy 0.000 description 3
- 108091064702 1 family Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- -1 GC boxes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 102000044689 Methyl-CpG binding protein MeCP2 Human genes 0.000 description 2
- 108700036642 Methyl-CpG binding protein MeCP2 Proteins 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 206010003883 azoospermia Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108700021031 cdc Genes Proteins 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000023715 cellular developmental process Effects 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000002980 germ line cell Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000006197 histone deacetylation Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000012470 leptotene Effects 0.000 description 2
- 210000002332 leydig cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008627 meiotic prophase Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 108091006107 transcriptional repressors Proteins 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000009353 zygotene Effects 0.000 description 2
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- LTIYJVAIGZYSAF-UHFFFAOYSA-N 4-(iminomethylideneamino)-2-methylbutan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CCN=C=N LTIYJVAIGZYSAF-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
- 102000019063 CCAAT-Binding Factor Human genes 0.000 description 1
- 108010026988 CCAAT-Binding Factor Proteins 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 241000271559 Dromaiidae Species 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241001466538 Gymnogyps Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010005832 Leukosialin Proteins 0.000 description 1
- 102000005931 Leukosialin Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700005079 Recessive Genes Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 101150093710 clec-87 gene Proteins 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000006543 gametophyte development Effects 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000001173 gonocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 102000054482 human CCNA2 Human genes 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
WO 00/29602 PCT/US99/08277 TRANSFECTION OF MALE GERM CELLS FOR GENERATION OF SELECTABLE TRANSGENIC STEM CELLS BACKGROUND OF THE INVENTION Throughout this application various publications are referenced within parentheses. 5 The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains. 1. THE FIELD OF THE INVENTION This invention relates to the medical arts, particularly to the field of transgenics and 10 gene therapy. The invention is particularly directed to the field of transgenic vertebrate stem cells. 2. DISCUSSION OF THE RELATED ART The field of transgenics was initially developed to understand the action of a single 15 gene in the context of the whole animal and phenomena of gene activation, expression, and interaction. This technology has been used to produce models for various diseases in humans and other animals. Transgenic technology is among the most powerful tools available for the study of genetics, and the understanding of genetic mechanisms and function. It is also used to study the relationship between genes and diseases. About 5,000 diseases are caused by a 20 single genetic defect. More commonly, other diseases are the result of complex interactions between one or more genes and environmental agents, such as viruses or carcinogens. The understanding of such interactions is of prime importance for the development of therapies, such as gene therapy and drug therapies, and also treatments such as organ transplantation. Such treatments compensate for functional deficiencies and/or may eliminate undesirable
I
WO 00/29602 PCT/US99/08277 functions expressed in an organism. Transgenesis has also been used for the improvement of livestock, and for the large scale production of biologically active pharmaceuticals. Historically, transgenic animals have been produced almost exclusively by micro injection of the fertilized egg. The pronuclei of fertilized eggs are micro-injected in vitro with 5 foreign, i.e., xenogeneic or allogeneic DNA or hybrid DNA molecules. The micro-injected fertilized eggs are then transferred to the genital tract of a pseudopregnant female. (E.g., P.J.A. Krimpenfort et al., Transgenic mice depleted in mature T-cells and methods for making transgenic mice, U.S. Pat. Nos. 5,175,384 and 5,434,340; P.J.A. Krimpenfort et al., Transgenic mice depleted in mature lymphocytic cell-type, U.S. Pat. No. 5,591,669). 10 The generation of transgenic animals by this technique is generally reproducible, and for this reason little has been done to improve on it. This technique, however, requires large numbers of fertilized eggs. This is partly because there is a high rate of egg loss due to lysis during micro-injection. Moreover manipulated embryos are less likely to implant and survive in utero. These factors contribute to the technique's extremely low efficiency. For example, 15 300-500 fertilized eggs may need to be micro injected to produce perhaps three transgenic animals. Partly because of the need to micro-inject large numbers of embryos, transgenic technology has largely been exploited in mice because of their high fecundity. While small animals such as mice have proved to be suitable models for certain diseases, their value in this respect is limited. Larger animals would be much more suitable to study the effects and 20 treatment of most human diseases because of their greater similarity to humans in many aspects, and also the size of their organs. Now that transgenic animals with the potential for human xenotransplantation are being developed, larger animals, of a size comparable to man will be required. Transgenic technology will allow that such donor animals will be immunocompatible with the human recipient. Historical transgenic techniques, however, 25 require that there be an ample supply of fertilized female germ cells or eggs. Most large mammals, such as primates, cows, horses and pigs produce only 10-20 or less eggs per animal per cycle even after hormonal stimulation. Consequently, generating large animals with these techniques is prohibitively expensive. This invention relies on the fact that spermatogenesis in male vertebrates produces vast 30 numbers of male germ cells that are more readily available than female germ cells. Most male mammals generally produce at least 10'spermatozoa (male germ cells) in each ejaculate. This 2 WO 00/29602 PCT/US99/08277 is in contrast to only 10-20 eggs in a mouse even after treatment with superovulatory drugs. A similar situation is true for ovulation in nearly all larger animals. For this reason alone, male germ cells will be a better target for introducing foreign DNA into the germ line, leading to the generation of transgenic animals with increased efficiency and after simple, natural 5 mating. Spermatogenesis is the process by which a diploid spermatogonial stem cell provides daughter cells which undergo dramatic and distinct morphological changes to become self propelling haploid cells (male gametes) capable, when fully mature, of fertilizing an ovum. Primordial germ cells are first seen in the endodermal yolk sac epithelium at E8 and 10 are thought to arise from the embryonic ectoderm (A. McLaren and Buehr, Cell Diff. Dev. 31:185 [1992]; Y. Matsui et al., Nature 353:750 [1991]). They migrate from the yolk sac epithelium through the hindgut endoderm to the genital ridges and proliferate through mitotic division to populate the testis. At sexual maturity the spermatogonium goes through 5 or 6 mitotic divisions before 15 it enters meiosis. The primitive spermatogonial stem cells (Ao/As) proliferate and form a population of intermediate spermatogonia types Apr, Aal, Al-4 after which they differentiate into type B spermatogonia. The type B spermatogonia differentiate to form primary spermatocytes which enter a prolonged meiotic prophase during which homologous chromosomes pair and recombine. The states of meiosis that are morphologically 20 distinguishable are; preleptotene, leptotene, zygotene, pachytene, secondary spermatocytes and the haploid spermatids. Spermatids undergo great morphological changes during spermatogenesis, such as reshaping the nucleus, formation of the acrosome and assembly of the tail (A.R. Bellve et al., Recovery, capacitation, acrosome reaction, andfractionation of sperm, Methods Enzymol. 225:113-36 [1993]). The spermatocytes and spermatids establish 25 vital contacts with the Sertoli cells through unique hemi-junctional attachments with the Sertoli cell membrane. The final changes in the maturing spermatozoan take place in the genital tract of the female prior to fertilization. Initially, attempts were made to produce transgenic animals by adding DNA to spermatozoa which were then used to fertilize mouse eggs in vitro. The fertilized eggs were 30 then transferred to pseudopregnant foster females, and of the pups born, 30% were reported to be transgenic and express the transgene. Despite repeated efforts by others, however, this 3 WO 00/29602 PCT/US99/08277 experiment could not be reproduced and no transgenic pups were obtained. Indeed, there remains little doubt that the transgenic animals reputed to have been obtained by this method were not transgenic at all and the DNA incorporation reported was mere experimental artifact. Data collected from laboratories around the world engaged in testing this method showed that 5 no transgenics were obtained from a total of 890 pups generated. In summary, it is currently possible to produce live transgenic progeny but the previously available methods are costly and extremely inefficient. Therefore, there is a definite need for a simple, less costly and less invasive method of producing transgenic animals. 10 There has also been a need for a way of selecting or isolating stem cells from non-stem cells, for study or therapeutic uses, that does not require the use of embryonic material, because the use of embryonic material may present ethical problems. In addition, the study of stem cells specifically in the physiologic milieu of non-embryonic (e.g., adult) vertebrates has been hampered by the difficulty of selecting, identifying, or isolating stem cells from non 15 stem cells in the tissues of these organisms. A stem cell is an undifferentiated mother cell that is self-renewable over the life of the organism and is multipotent, i.e., capable of generating various committed progenitor cells that can develop into fully mature differentiated cell lines. (T. Zigova and P.R. Sanberg, The rising star of neural stem cell research, Nature Biotechnol. 16(11):1007-08 [1998]). All 20 vertebrate tissues arise from stem cells, including hematopoietic stem cells, from which various types of blood cells derive; neural stem cells, from which brain and nerve tissues derive; and germ cells, from which male or female gametes derive. Recently, there has been a great deal of interest in transgenic stem cells as a potential therapeutic tool for patients suffering from genetic diseases, metabolic defects, varying kinds 25 of trauma, diseases of the nervous system, or cancers of the blood. In manipulating stem cells in vitro or in vivo it is important to be able to identify and select stem cells of interest from non-stem cells. Tsukamoto et al. disclosed a method for identifying human hematopoietic stem cells based on specific antibody binding to Thy-1 and CD34 surface epitopes. (A.Tsukamoto et al., 30 Identification and isolation of human hematopoietic stem cells, U.S. Pat. No. 5,643,741). Tsukamoto et al. taught embodiments of their method in which the antibodies are labeled with 4 WO 00/29602 PCTIUS99/08277 a fluorochrome and detection of stem cells is by fluorescence activated cell sorter (FACS). Murray et al. taught a method of purifying a population of hematopoietic stem cells expressing a CDw109 marker that used binding of monoclonal antibodies specific for Cdwl09. (L. Murray et al., Method of purifying a population of cells enriched for 5 hematopoietic stem cells, populations of cells obtained thereby and methods of use thereof, U.S. Pat. No. 5,665,557). Transgenic neural stem cells (NSCs) have also been identified and selected using immunofluorescence or other immunostaining techniques. (J.D. Flax et al., Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign 10 genes, Nature Biotechnol. 16(11):1033-39 [1998]; 0. Bruestle et al., Chimeric brains generated by intraventricular transplantation offetal human brain cells into embryonic rats, Nature Biotechnol. 16(11):1040-44 [1998]). However, such immunologically based methods as these have limited usefulness in identifying or selecting stem cells, because they rely on tissue- or lineage-specific epitopes and 15 do not consistently leave the cells in a viable condition. Others have addressed the latter problem using non-lethal methods for labeling transgenic cells, particularly using genes encoding fluorescent or bioluminescent markers. For example, Chalfie et al. disclosed a recombinant DNA molecule comprising the green fluorescent protein gene operatively linked to any exogenous regulatory element. (M. Chalfie et al., Uses ofgreen-fluorescent protein, 20 U.S. Pat. No. 5,491,084). Cormier et al. taught a recombinant DNA vector comprising the gene for apoaequorin, a bioluminescent protein. (M.J. Cormier et al., Recombinant DNA vectors capable of expressing apoaequorin, USPN 5,422,266). Contag et al. disclosed a method for detecting a transformed cell of interest expressing a light-generating moiety in vivo. (C.H. Contag, Non-invasive localization ofa light-emitting 25 conjugate in a mammal, U.S. Pat. No. 5,650,135). Similarly, Horan et al. disclosed a method for tracking cells in vivo related to labeling cells with a fluorecent cyanine dye. (P.K. Horan et al., In vivo cellular tracking, U.S. Pat. No. 4,762,701). And Patterson et al. taught a method of detecting cells expressing a specific nucleotide target sequence by using fluorescently labeled complementary nucleic acid probes and fluorescence-activated flow 30 cytomety (FACS). (Patterson et al., Method of detecting amplified nucleic sequences in cells byflow cytometry, U.S. Pat. No. 5,840,478). 5 WO 00/29602 PCT/US99/08277 Lineage specific stem cell promoters and other regulatory elements are available that could be linked to the expression of a marker gene. For example, Bum et al. taught the use of a CD34 promoter, specific to hematopoietic stem cells. (T.C. Bum et al., Hematopoietic stem cell specific gene expression, U.S. Pat. No. 5,556,954). 5 Gay disclosed a method of isolating a lineage specific stem cell in vitro. (D.A. Gay, Method of isolating a lineage specific stem cell in vitro, U.S. Patent No. 5,639,618). The method involved in vitro transfection of pluripotent embryonic stem cells with a construct comprising a lineage specific promoter sequence operably linked to a DNA encoding a fluorescent or other reporter protein. But this method was not applicable in a generalized way 10 to selecting stem cells in vitro or in vivo in transgenic animals. For this purpose, there has been a definite need for a promoter sequence that operates in a wide variety of stem cells, rather than regulating transcription in a lineage specific manner. The differentiation of stem cells into somatic cells as well as normal cell growth depend on the regulation of the cell cycle. Dysfunction of this regulation can lead to 15 uncontrolled cell growth and cancer (L.H. Hartwell and M.B. Kastan, Cell cycle control and cancer, Science 266:1821-28 [1994]). Important in the regulation of growth and differentiation are the cyclins. Cyclins are positive regulators of cyclin-dependent kinases (CDKs), with which they can form activated complexes that play a central role in driving the cell through the cell cycle. The activities of these CDK's are regulated by sequential 20 activating and inactivating phosphorylation and de-phosphorylation events. (D.O. Morgan, Principles of CDK regulation, Nature (Lond.) 374:131-34 [1995]; C.J. Sherr, Phase progression: cycling on cue, Cell 79:551-555 [1994]; P. Nurse, Ordering S phase and M phase in the cell cycle, Cell 79:547-50 [1994]). Negative regulators called CDK inhibitors can bind to and inhibit CDK's, adding another layer of regulation (T. Hirama and H.P. 25 Koeffier, Role ofthe cyclin-dependent kinase inhibitors in the development of cancer, Blood 86:841-54 [1995]; C.J. Sherr and J.M. Roberts, Inhibitors ofmammalian G1 cyclin-dependent kinases, Genes Dev. 9:1149-1163 [1995]). The kinase activity of the cyclin A/CDK2 complex, which rises at the G, to S transition, is required for entry into S phase (K.A. Heichman and J.M. Roberts, Rules to 30 replicate by, Cell 79:557-62 [1994]; M. Pagano et al., Cyclin A is required at two points in the human cell cycle, EMBO J. 11:961-71 [1992]; J. Pines and T. Hunter, Human cyclin A is 6 WO 00/29602 PCTIUS99/08277 adenovirus EJA-associated protein p60 and behaves differently from cyclin B, Nature 346:760-63 [1990]; C. Desdouets et al., Cyclin A: function and expression during cell proliferation, Prog. Cell Cycle Res. 1:15-23 [1995]). Cyclin A also forms a complex with CDC2, the activity of which peaks at the G 2 to M transition, and the kinase activity of cyclin 5 A/CDC2 is also required for M-phase entry (M. Pagano et al. [1992]). Two kinds of cyclin A were first found in Xenopus; early embryos contained both cyclin Al and cyclin A2. Later in development, cyclin A2, which shares considerable homology to mammalian cyclin A2, was found throughout the embryo, whereas cyclin Al was found only in the testis and ovary. ( J.A. Howe et al., Identification of a developmental 10 timer regulating the stability of embryonic cyclin A and a new somatic A-type cyclin at gastrulation, Genes Dev. 9(10):164-76 [1995]). In the mouse, cyclin A2 was found in a number of tissues during development, but cyclin Al expression was highly restricted, with high levels measured in late pachytene spermatocytes. (C. Sweeney et al., A distinct cyclin A is expressed in germ cells in the mouse, Development 122(1):53-64 [1996]). 15 Cyclin Al is not expressed in fully differentiated cells of non-embryonic tissues, but can be expressed in a wide variety of stem cells, including male and female germ cells, brain stem cells, hematopoietic progenitor cells, as well as in a majority of myeloid leukemic cells and undifferentiated hematological malignancies. (R. Yang et al., Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines, 20 Cancer Res. 57(5):913-20 [1997]; A. Kramer et al., Cyclin A] is predominantly expressed in hematological malignancies with myeloid differentiation, Leukemia 12(6):893-98 [1998]; C. Sweeney et al. [1996]; J.A. Howe et al. [1995]). The pattern of cyclin Al expression indicates that its regulation differs from that of cyclin A2, and this may be related to differential binding by cyclin Al and cyclin A2 promoters of transcriptional initiation factors, 25 such as the Spi family of initiation factors. The Spl family of initiation factors is related to the regulation of differentiation in stem cells. (K.L. Block et al., Blood 88:2071-80 [1996]; H.M. Chen et al., J. Biol. Chem. 268:8230-39 [1993]; R.K. Margana et al., J. Biol. Chem. 272:3083-90 [1997]). Spl is expressed at high levels in tissues where cyclin Al expression is found. (C. Sweeney et al. 30 [1996]). Also, induction of Spl was found to be associated with differentiation of embryonal carcinoma cells and SpI was causally linked to expression of the fibronectin gene, providing 7 WO 00/29602 PCT/US99/08277 evidence for a role of SpI in differentiation. (M. Suzuki et al., Molecular & Cellular Biology 18: 3010-3020 [1998]). In adult tissue, high levels of SpI have been reported in hematopoietic progenitors and in the later stages of spermatogenesis. (J.D. Safer et al., Molecular & Cellular Biology 11: 2189-2199 [1991]). 5 Levels of SpI vary up to 10-fold in different tissues. (J.D.Safer et al. [1991]). This could provide a basis for directing tissue specific expression in stem cells, especially if the affinity of the cis-acting SpI family binding sites of various promoters differ. Another mechanism of tissue-directed expression depends on the molar ratios of Spl family members to each other resulting in either activation or repression of transcription. (A.P. Kumar et al., 10 Nucleic Acids Res. 25:2012-19 [1997]; M.J. Birnbaum et al., Biochem.. 34:16503-08 [1995]). Spl has been shown to serve distinct roles in transcriptional activation: it can directly interact with the basal transcription complex. (A. Emili et al., Molec. Cell. Biol. 14:1582 93 [1994]) and it can determine the transcription start site in TATA-less promoters (J. Lu et 15 al., J. Biol. Chem. 269:5391-5402 [1994]). However, SpI can also function as a more general transcriptional activator, and an SpI family member, Sp3 protein, is known to function either as transcriptional activator or repressor depending on the context of the binding site in a promoter. (D. Apt et al., Virol. 224:281-91 [1996]; B. Majello et al., J. Biol. Chem. 272:4021-26 [1997]). When Sp3 binds to a single site, it can activate transcription but 20 binding to multiple sites can lead to strong transcriptional repression ( M.J. Birnbaum et al., Biochem.. 34:16503-08 [1995]). Also, since myb was shown to be expressed in male germs cells, myb probably acts as an important transcriptional factor for expression from the cyclin Al promoter during spermatogenesis as well as hematopoiesis. (J. Sitzmann et al., Expression ofB-Myb during 25 mouse embryogenesis, Oncogene 12:1889-94 [1996]; K. Latham et al., Oncogene 13:1161-68 [1998]). The structure of myb protein includes a helix-turn-helix motif involved with DNA recognition. (M.D. Carr et al., Eur. J. Biochem. 235:721-735 [1996]). The myb proteins bind DNA as monomers, with cooperative binding of the R2 and R3 regions within the major groove to the consensus myb binding site, MBS (c/TAAcNG). (K.M. Howe and R.J. Watson, 30 EMBO J. 9:161-69 [1990]; K. Ogata et al., Nature Struct. Biol. 2:309-20 [1995]). The precise role of myb transcription factors in cell cycle regulation is unknown but as a transcriptional 8 WO 00/29602 PCT/US99/08277 activator they may be important for the activation of cell cycle genes such as cyclin Al. (Reviews: S.A. Ness, Biochim Biophys. Acta 1288:F123-F139 [1996]; M.K. Saville and R.J. Watson, Adv. Cancer Res. 72:109-40 [1998]). The present invention addresses the need for spermatogenic transfection, either in vitro 5 or in vivo, that is highly effective in transferring allogeneic as well as xenogeneic genes into the animal's germ cells and in producing transgenic vertebrate animals. The present technology addresses the requirements of germ line and stem cell line gene therapies in humans and other vertebrate species. Further, the method of the present invention particularly addresses the problem of identifying and selecting stem cells from non-stem cells including 10 differentiated somatic cells, especially from non-embryonic biological sources. These and other benefits and features of the present invention are described herein. SUMMARY OF THE INVENTION The present invention relates to the in vivo and ex vivo (in vitro) transfection of eukaryotic animal germ cells with a desired genetic material. Briefly, the in vivo method 15 involves injection of genetic material together with a suitable vector directly into the testicle of the animal. In this method, all or some of the male germ cells within the testicle are transfected in situ, under effective conditions. The ex vivo method involves extracting germ cells from the gonad of a suitable donor or from the animal's own gonad, using a novel isolation method, transfecting them in vitro, and then returning them to the testis under 20 suitable conditions where they will spontaneously repopulate it. The ex vivo method has the advantage that the transfected germ cells may be screened by various means before being returned to the testis to ensure that the transgene is incorporated into the genome in a stable state. Moreover, after screening and cell sorting only enriched populations of germ cells may be returned. This approach provides a greater chance of transgenic progeny after mating. 25 This invention also relates to a novel method for the isolation of spermatogonia, comprising obtaining spermatogonia from a mixed population of testicular cells by extruding the cells from the seminiferous tubules and gentle enzymatic disaggregation. The spermatogonia or stem cells which are to be genetically modified, may be isolated from a mixed cell population by a novel method including the utilization of a promoter sequence, 30 which is only active in stem cells, for example the cyclin Al promoter, or in cycling 9 WO 00/29602 PCTIUS99/08277 spermatogonial stem cell populations, for example, B-Myb promoter or a spermotogonia specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM (ataxia telangiectasia) promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI 5 (from fragile X site) promoter, optionally linked to a reporter construct, for example, a construct encoding Green Fluorescent Protein (EGFP), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of ultraviolet light. These unique promoter sequences drive the expression of the reporter construct only in the cycling 10 spermatogonia or stem cells in which they operate. The spermatogonia or stem cells, thus, are the only cells in the mixed population which will express the reporter construct and they, thus, may be isolated on this basis. Transgenic cells expressing a fluorescent reporter construct can be sorted with the aid of, for example, a flow activated cell sorter (FACS) set at the appropriate wavelength or they may be selected by chemical methods. 15 The present invention also relates to a method of obtaining selectable transgenic stem cells by transfecting a male germ cell with a DNA construct comprising a stem cell-specific promoter, for example, a cyclin Al promoter, operatively linked to a gene encoding a fluorescent or light-emitting reporter protein. The present invention also relates to selectable transgenic stem cells that have stably integrated the DNA and non-human transgenic 20 vertebrates comprising them. In stem cells other than germ cells, expression of the reporter gene from a cyclin Al promoter in vivo is facilitated by preventing the methylation of promoter DNA by the use of flanking insulator elements. Alternatively, when transgenic stem cells are grown in vitro, inhibitors of DNA methylation can be added to the culture medium. For transfection, the method of the invention comprises administering to the animal, 25 or to germ cells in vitro, a composition comprising amounts of nucleic acid comprising polynucleotides encoding a desired trait. In addition, the composition comprises, for example, a relevant controlling promoter region made up of nucleotide sequences. This is combined with, for example, a gene delivery system comprising a cell transfection promotion agent such as retro viral vectors, adenoviral and adenoviral related vectors, or liposomal reagents or other 30 agents used for gene therapy. These introduced under conditions effective to deliver the nucleic acid segments to the animal's germ cells optionally with the polynucleotide inserted 10 WO 00/29602 PCT/US99/08277 into the genome of the germ cells. Following incorporation of the DNA, the treated animal is either allowed to breed naturally, or reproduced with the aid of assisted reproductive technologies, and the progeny selected for the desired trait. This technology is applicable to the production of transgenic animals for use as 5 animal models, and to the modification of the genome of an animal, including a human, by addition, modification, or subtraction of genetic material, often resulting in phenotypic changes. The present methods are also applicable to altering the carrier status of an animal, including a human, where that individual is carrying a gene for a recessive or dominant gene disorder, or where the individual is prone to pass a multigenic disorder to his offspring. 10 A preparation suitable for use with the present methods comprises a polynucleotide segment encoding a desired trait and a transfection promotion agent, and optionally an uptake promotion agent which is sometime equipped with agents protective against DNA breakdown. The different components of the transfection composition (mixture) are also provided in the form of a kit, with the components described above in measured form in two or more separate 15 containers. The kit generally contains the different components in separate containers and instructions for effective use. Other components may also be provided in the kit as well as a carrier. Thus the present technology is of great value in the study of stem cells and cellular development, and in producing transgenic vertebrate animals as well as for repairing genetic 20 defects. The present technology is also suitable for germ line and stem cell line gene therapy in humans and other vertebrate animal species. The present invention is also valuable in identifying cell lineages before full differentiation to facilitate modification and/or engineering of specific tissues in vitro for their subsequent transplantation in the treatment of disease or trauma. 25 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 represents a map of DNA construct pCyclinA 1 -EGFP-1. Figure 2 represents transcriptional start sites in the human cyclin Al gene. Figure 3 represents 5' upstream region of the human cyclin Al gene. Figure 4 represents transactivation activity of cyclin Al promoter fragments in Hela 30 cells. 11 WO 00/29602 PCTIUS99/08277 Figure 5 shows activity of the cyclin Al promoter fragments in the Drosophila cell line S2. Figure 6 shows effects of GC box (Sp 1 site) mutations on promoter activity. Figure 7 shows cell cycle regulated activity of the cyclin Al promoter in Hela cells. 5 Figure 8 shows germ line-specific expression of EGFP from a human cyclin Al promoter in murine testicular tissue. Figure 9 shows the positive association of cyclin Al promoter methylation with silencing of a cyclin Al promoter - EGFP transgene in MG63 cells and the repression of cyclin Al promoter activity by methylation and MeCP2 in S2 Drosophila cells. 10 Figure 10 shows a comparison of reporter gene expression from different promoters, including the cyclin Al promoter, in cell lines from various tissues. Figure 11 shows transactivation of the cyclin Al promoter by c-myb. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention arose from a desire by the present inventors to improve on 15 existing methods for the genetic modification of an animal's germ cells and for producing transgenic animals. The pre-existing art methods rely on direct injection of DNA into zygotes produced in vitro or in vivo, or by the production of chimeric embryos using embryonal stem cells incorporated into a recipient blastocyst. Following this, such treated embryos are transferred to the primed uterus or oviduct. The available methods are extremely slow and 20 costly, rely on several invasive steps, and only produce transgenic progeny sporadically and unpredictably. In their search for a less costly, faster, and more efficient approach for producing transgenics, the present inventors devised the present method which relies on the in vivo or ex vivo (in vitro) transfection of male animal germ cells with a nucleic acid segment encoding 25 a desired trait. The present method relies on at least one of the following strategies. A first method delivers the nucleic acid segment using known gene delivery systems in situ to the gonad of the animal (in vivo transfection), allows the transfected germ cells to differentiate in their own milieu, and then selects for animals exhibiting the nucleic acid's integration into its germ cells (transgenic animals). The thus selected animals may be mated, or their sperm 30 utilized for insemination or in vitro fertilization to produce transgenic progeny. The selection 12 WO 00/29602 PCT/US99/08277 may take place after biopsy of one or both gonads, or after examination of the animal's ejaculate amplified by the polymerase chain reaction to confirm the incorporation of the desired nucleic acid sequence. In order to simplify the confirmation of the actual incorporation of the desired nucleic acid, the initial transfection may include a co-transfected 5 reporter gene, such as a gene encoding for Green Fluorescent Protein (or encoding enhanced Green Fluorescent Protein [EGFP]), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under a suitable wave-length of ultraviolet light. Alternatively, male germ cells may be isolated from a donor animal and transfected, 10 or genetically altered in vitro to impart the desired trait. Following this genetic manipulation, germ cells which exhibit any evidence that the DNA has been modified in the desired manner are selected, and transferred to the testis of a suitable recipient animal. Further selection may be attempted after biopsy of one or both gonads, or after examination of the animal's ejaculate amplified by the polymerase chain reaction to confirm whether the desired nucleic acid 15 sequence was actually incorporated. As described above, the initial transfection may have included a co-transfected reporter gene, such as a gene encoding the Green Fluorescent Protein (or enhanced Green Fluorescent Protein [EGFP]), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under light of suitable wave-lengths. Before transfer of the germ 20 cells, the recipient testis are generally treated in one, or a combination, of a number of ways to inactivate or destroy endogenous germ cells, including by gamma irradiation, by chemical treatment, by means of infectious agents such as viruses, or by autoimmune depletion or by combinations thereof. This treatment facilitates the colonization of the recipient testis by the altered donor cells. 25 Animals that were shown to carry suitably modified sperm cells then may be either allowed to mate naturally, or alternatively their spermatozoa are used for insemination or in vitro fertilization. The thus obtained transgenic progeny may be bred, whether by natural mating or artificial insemination, to obtain further transgenic progeny. The method of this invention has a lesser number of invasive procedures than other available methods, and a high 30 rate of success in producing incorporation into the progeny's genome of the nucleic acid sequence encoding a desired trait. 13 WO 00/29602 PCT/US99/08277 Primordial germ cells are thought to arise from the embryonic ectoderm, and are first seen in the epithelium of the endodermal yolk sac at the E8 stage. From there they migrate through the hindgut endoderm to the genital ridges. The primitive spermatogonial stem cells, known as AO/As, differentiate into type B spermatogonia. The latter further differentiate to 5 form primary spermatocytes, and enter a prolonged meiotic prophase during which homologous chromosomes pair and recombine. Several morphological stages of meiosis are distinguishable : preleptotene, leptotene, zygotene, pachytene, secondary spermatocytes, and the haploid spermatids. The latter undergo further morphological changes during spermatogenesis, including the reshaping of their nucleus, the formation of acrosome, and 10 assembly of the tail. The final changes in the spermatozoon take place in the genital tract of the female, prior to fertilization. The uptake of the nucleic acid segment administered by the present in vivo method to the gonads will reach germ cells that are at one or more of these stages, and be taken up by those that are at a more receptive stage. In the ex vivo (in vitro) method of genetic modification, generally only diploid spermatogonia are used for nucleic 15 acid modification. The cells may be modified in vivo using gene therapy techniques, or in vitro using a number of different transfection strategies. The inventors are, thus, providing in this patent a novel and unobvious method for isolation of male germ cells, and for the in vivo and ex vivo (in vitro) transfection of allogeneic as well as xenogeneic DNA into an animal's germ cells. This comprises the 20 administration to an animal of a composition comprising a gene delivery system and at least one nucleic acid segment, in amounts and under conditions effective to modify the animal's germ cells, and allowing the nucleic acid segment to enter, and be released into, the germ cells, and to integrate into their genome. The in vivo introduction of the gene delivery mixture to the germ cells may be 25 accomplished by direct delivery into the animal's testis (es), where it is distributed to male germ cells at various stages of development. The in vivo method utilizes novel technology, such as injecting the gene delivery mixture either into the vasa efferentia, directly into the seminiferous tubules, or into the rete testis using, for example, a micropipette. To ensure a steady infusion of the gene delivery mixture, under pressures which will not damage the 30 delicate tubule system in the testis, the injection may be made through the micropipette with the aid of a picopump delivering a precise measured volume under controlled amounts of 14 WO 00/29602 PCTIUS99/08277 pressure. The micropipette may be made of a suitable material, such as metal or glass, and is usually made from glass tubing which has been drawn to a fine bore at its working tip, e.g. using a pipette puller. The tip may be angulated in a convenient manner to facilitate its entry into the testicular tubule system. The micropipette may be also provided with a beveled 5 working end to allow a better and less damaging penetration of the fine tubules at the injection site. This bevel may be produced by means of a specially manufactured grinding apparatus. The diameter of the tip of the pipette for the in vivo method of injection may be about 15 to 45 microns, although other sizes may be utilized as needed, depending on the animal's size. The tip of the pipette may be introduced into the rete testis or the tubule system of the testicle, 10 with the aid of a binocular microscope with coaxial illumination, with care taken not to damage the wall of the tubule opposite the injection point, and keeping trauma to a minimum. On average, a magnification of about x25 to x80 is suitable, and bench mounted micromanipulators are not severally required as the procedure may be carried out by a skilled artisan without additional aids. A small amount of a suitable, non-toxic dye, may be added 15 to the gene delivery fluid to confirm delivery and dissemination to the tubules of the testis. It may include a dilute solution of a suitable, non-toxic dye, which may be visualized and tracked under the microscope. In this manner, the gene delivery mixture is brought into intimate contact with the germ cells. The gene delivery mixture typically comprises the modified nucleic acid encoding 20 the desired trait, together with a suitable promoter sequence, and optionally agents which increase the uptake of the nucleic acid sequence, such as liposomes, retroviral vectors, adenoviral vectors, adenovirus enhanced gene delivery systems, or combinations thereof. A reporter construct such as the gene encoding for Green Fluorescent Protein may further be added to the gene delivery mixture. Targeting molecules such as c-kit ligand may be added 25 to the gene delivery mixture to enhance the transfer of the male germ cell. For the ex vivo (in vitro) method of genetic alteration, the introduction of the modified germ cells into the recipient testis may be accomplished by direct injection using a suitable micropipette. Support cells, such as Leydig or Sertoli cells that provide hormonal stimulus to spermatogonial differentiation, may be transferred to a recipient testis along with the 30 modified germ cells. These transferred support cells may be unmodified, or, alternatively, may themselves have been transfected, together with- or separately from the germ cells. 15 WO 00/29602 PCT/US99/08277 These transferred support cells may be autologous or heterologous to either the donor or recipient testis. A preferred concentration of cells in the transfer fluid may easily be established by simple experimentation, but will likely be within the range of about 1 x 10' 10 x 1 0'cells per 10 pl of fluid. This micropipette may be introduced into the vasa efferentia, 5 the rete testis or the seminiferous tubules, optionally with the aid of a picopump to control pressure and/or volume, or this delivery may be done manually. The micropipette employed is in most respects similar to that used for the in vivo injection, except that its tip diameter generally will be about 70 microns. The microsurgical method of introduction is similar in all respects to that used for the in vivo method described above. A suitable dyestuff may also 10 be incorporated into the carrier fluid for easy identification of satisfactory delivery of the transfected germ cells. Once in contact with germ cells, whether they are in situ in the animal or vitro, the gene delivery mixture facilitates the uptake and transport of the xenogeneic genetic material into the appropriate cell location for integration into the genome and expression. A number 15 of known gene delivery methods may be used for the uptake of nucleic acid sequences into the cell. "Gene delivery (or transfection) mixture", in the context of this patent, means selected genetic material together with an appropriate vector mixed, for example, with an effective amount of lipid transfecting agent. The amount of each component of the mixture is chosen 20 so that the transfection of a specific species of germ cell is optimized. Such optimization requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1: 1, although other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial. "Transfecting agent", as utilized herein, means a composition of matter added to the 25 genetic material for enhancing the uptake of exogenous DNA segment(s) into a eukaryotic cell, preferably a mammalian cell, and more preferably a mammalian germ cell. The enhancement is measured relative to the uptake in the absence of the transfecting agent. Examples of transfecting agents include adenovirus-transferrin-polylysine-DNA complexes. These complexes generally augment the uptake of DNA into the cell and reduce its 30 breakdown during its passage through the cytoplasm to the nucleus of the cell. These complexes may be targeted to the male germ cells using specific ligands which are recognized 16 WO 00/29602 PCT/US99/08277 by receptors on the cell surface of the germ cell, such as the c-kit ligand or modifications thereof. Other preferred transfecting agents include lipofectin, lipfectamine, DIMRIE C, Superfect, and Effectin (Qiagen). Although these are not as efficient transfecting agents as 5 viral transfecting agents, they have the advantage that they facilitate stable integration of xenogeneic DNA sequence into the vertebrate genome, without size restrictions commonly associated with virus-derived transfecting agents. "Virus", as used herein, means any virus, or transfecting fragment thereof, which may facilitate the delivery of the genetic material into male germ cells. Examples of viruses which 10 are suitable for use herein are adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of 15 the desired DNA segment by, and release into, the cytoplasm of germ cells and mixtures thereof. The mumps virus is particularly suited because of its affinity for immature sperm cells including spermatogonia. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems, however, may also be utilized within the confines of the invention. 20 "Genetic material", as used herein, means DNA sequences capable of imparting novel genetic modification(s), or biologically functional characteristic(s) to the recipient animal. The novel genetic modification(s) or characteristic(s) may be encoded by one or more genes or gene segments, or may be caused by removal or mutation of one or more genes, and may additionally contain regulatory sequences. The transfected genetic material is preferably 25 functional, that is it expresses a desired trait by means of a product or by suppressing the production of another. Examples of other mechanisms by which a gene's function may be expressed are genomic imprinting, i.e. inactivation of one of a pair of genes (alleles) during very early embryonic development, or inactivation of genetic material by mutation or deletion of gene sequences, or by repression of a dominant negative gene product, among others. 30 In addition, novel genetic modification(s) may be artificially induced mutations or variations, or natural allelic mutations or variations of a gene(s). Mutations or variations may 17 WO 00/29602 PCTIUS99/08277 be induced artificially by a number of techniques, all of which are well known in the art, including chemical treatment, gamma irradiation treatment, ultraviolet radiation treatment, ultraviolet radiation, and the like. Chemicals useful for the induction of mutations or variations include carcinogens such as ethidium bromide and others known in the art. 5 DNA segments of specific sequences may also be constructed to thereby incorporate any desired mutation or variation or to disrupt a gene or to alter genomic DNA. Those skilled in the art will readily appreciate that the genetic material is inheritable and is, therefore, present in almost every cell of future generations of the progeny, including the germ cells. Among novel characteristics are the expression of a previously unexpressed trait, 10 augmentation or reduction of an expressed trait, over expression or under expression of a trait, ectopic expression, that is expression of a trait in tissues where it normally would not be expressed, or the attenuation or elimination of a previously expressed trait. Other novel characteristics include the qualitative change of an expressed trait, for example, to palliate or alleviate, or otherwise prevent expression of an inheritable disorder with a multigenic basis. 15 For the expression of transfected genetic material to obtain a desired trait, a promoter sequence is operably linked to a polynucleotide sequence encoding the desired trait or product. A promoter sequence is chosen that operates in the cell type of interest. A promoter sequence, which is only active in cycling spermatogonial stem cell populations can be used for differential expression in male germ cells, for example, B-Myb 20 or a spermotogonia specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM (ataxia-telangiectasia) promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI (from fragile X site) promoter. The human cyclin Al promoter region is a most preferred promoter sequence for 25 driving the expression of a reporter construct or for driving the expression of another desired xenogeneic gene sequence, when expression is desired in germ cells, hematopoietic cells, other stem cells of a vertebrate. The following nucleotide sequence represents the 5' end of the human cyclin Al gene. An untranscribed region extends from nucleotide -1299 to -1; a transcribed but untranslated 30 region extends from +1 to +127, where the first ATG sequence begins; also represented are cyclin Al exon 1 (+1 to +234), intron 1 (+235 to +537), and part of exon 2 (beginning at 18 WO 00/29602 PCT/US99/08277 +53 8), with transcribed regions being underlined and the translational start site at nt. +127 to +129 being bolded: -1299 TCGATCTGAT TTAGAGATTT AGGGATGGAT GTTTTAAAAA AAGCAAAAGT -1249 AGTAACAGAC TATAGCATTG GTAATGTGTG TGTGCATATA TACATATTAT 5 -1199 TTTTAAAAAA ATAAAGTTCG ATTATTTCAC CTGGCTTGTC AGTCACCTAT -1149 GCAGGCGTCT GAGCCCCCGG GTTTCCAGGA GCCCCCCGTA TAAGGACCCC -1099 AGGGACTCCT CTCCCCACGC GGCCGGGCCG CCCGCCCGGC CCCCAGCCCG -1049 GAGAGCTGCC ACCGACCCCC TCAACGTCCC AAGCCCCAGC TCTGTCGCCC -0999 GCGTTCCTTC CTCTTCCTGG GCCACAATCT TGGCTTTCCC GGGCCGGCTT 10 -0949 CACGCAGTTG CGCAGGAGCC CGCGGGGGAA GACCTCTCGTGGGGACCTCG -0899 AGCACGACGT GCGACCCTAA ATCCCCACAT CTCCTCTGCC GCCTCGCAGG -0849 CCACATGCAC CGGGAGCCGG GCGGGGCAGG CGCGGCCCGC AAGGACCCCC -0799 GCGATGGAGA CGCAACACTG CCGCGACTGC ACTTGGGGCA GCCCCGCCGC -0749 GTCCCAGCCG CCTCCCGGCA GGAAGCGTAG GTGTGTGAGC CGACCCGGAG 15 -0699 CGAGCCGCGC CCTCGGGCCA GCGTGGGCAG GGCGCCGCAG CCTGCGCAGC -0649 CCCGAGGACC CCGCGTCGCT CTCCCGAGCC AGGGTTCTCA GGAGCGGGCC -0599 GCGCAGGAGA CGTTAGAGGG GGTTGTTAGC GGCTGTTGGG AGAACGGGTC -0549 ACGGAAACAG TCCCTTCCAA AGCCGGGGCC ATCGTGGGGT GGGCGAGTCC -0499 GCCCTCCCAG GCCGGGGGCG CGGACCAGAG GGGACGTGTG CAGACGGCCG 20 -0449 CGGTCAGCCC CACCTCGCCC GGGCGGAGAC GCACAGCTGG AGCTGGAGGG -0399 CCGTCGCCCG TTGGGCCCTC AGGGGCCTGA ACGCCCAGGG GTCGCGGCGA -0349 GTCCACCCGG AGCGAGTCAG GTGAGCAGGT CGCCATGGCG ATGCGGCCCC -0299 GGAGAGCGCA CGCCTGCCGC GGTCGGCATG GAAACGCTCC CGCTAGGTCC -0249 GGGGGCGCCG CTGATTGGCC GATTCAACAG ACGCGGGTGG GCAGCTCAGC 25 -0199 CGCATCGCTA AGCCCGGCCG CCTCCCAGGC TGGAATCCCT CGACACTTGG -0149 TCCTTCCCGC CCCGCCCTTC CGTGCCCTGC CCTTCCCTGC CCTTCCCCGC -0099 CCTGCCCCGC CCGGCCCGGC CCGGCCCTGC CCAACCCTGC CCCGCCCTGC -0049 CCCGCCCAGC CGGCCACCTC TTAACCGCGA TCCTCCAGTG CACTTGCCAG +0003 TTGTTCCGGA CACATAGAAA GATAACGACG GGAAGACGGG GCCCCGTTTG 30 +0053 GGGTCCAGGC AGGTTTTGGG GCCTCCTGTC TGGTGGGAGG AGGCCGCAGC +0103 GCAGCACCCT GCTCGTCACT TGGGATGGAG ACCGGCTTTC CCGCAATCAT +0153 GTACCCTGGA TCTTTTAT TG GGGGCTGGGG AGAAGAGTAT CTCAGCTGGG +0203 AAGGACCGGG GCTCCCAGAT TTCGTCTTCC AGGTAACGTG GGTTTAGTAT 19 WO 00/29602 PCT/US99/08277 +0253 CCCGACTTGG AGGCTTGTCA GAATGTTTCT CTCCTTCCAG CCCAACACGA +0303 AGTCTTGGGA TAAAAAGCCT CCCTCAGGGA TTCAAATAAC TGTTTTGATT +0353 CAGAGCAACT TTGATCGCCT GTGCGGTCGC ACCTGCCCTT TCAGCCCCAA +0403 TAATTACTGG GAAGATCAGC AATTGGTGTT AGTCCCATTG CTTGGTGCTC 5 +0453 TCCCTCCTAG AGGTTCGCTG TGTCCTTGGA GCCCGGGGTG GACGGAATCG +0503 ACTAAACAGC TTGTCTGTTT CTCTTTCCCT GGTAGCAGCA GCCCGTGGAG +0553 TCTGAAGCAA TGCACTGCAG CAACCCCAAG AGTGGAGTTG TGCTGGCTAC +0603 AGTGGCCCGA GGTCCCGATG CTTGTCAGAT ACTCACCAGA GCCCCGCTGG +0653 GCCAGGAT (SEQ. ID. NO.: 1). 10 A most preferred embodiment of the cyclin Al promoter of the present invention is a DNA fragment with the sequence of nt. -1299 to +144, inclusive, having the first translational start site (the ATG in bold at nt. +127 to +129 of the human sequence above) changed to ATT (SEQ. ID. NO.2). Other preferred embodiments of a cyclin Al promoter include any operative fragment of SEQ. ID. NO.:2 or non-human homologue thereof, or an 15 operative derivative of any of these. Preferred examples of an operative fragment include the -1151 to +144 fragment (SEQ. ID. NO.:3), the -454 to +144 fragment (SEQ. ID. NO.:4), the -326 to +144 fragment (SEQ. ID. NO.:5), the -190 to +144 fragment (SEQ. ID. NO.:6), the -160 to +144 fragment (SEQ. ID. NO.:7), the -120 to +144 fragment (SEQ. ID. NO.:8), the -112 to +144 fragment (SEQ. ID. NO.:9), all with ATG at +127 to +129 changed as described 20 above. But any cyclin Al promoter fragment that includes the nucleotide sequence extending from nt. -112 downstream to at least nt. +5 or beyond, up to and including nt. +144, is also operative and useful, as long as the translational start site at +127 to +129 is no longer intact and the essential Spl binding sites between -112 and -37 (GC Box Nos. 1, 2, and 3 and/or 4) are intact, as described below. Other preferred fragments, in accordance with the present 25 invention, include those extending from -190 to +20 (SEQ. ID. NO.:10), or from +190 to any nucleotide between nt. +20 up to nt. +144 (without the translational start site). But shorter fragments such as -190 to +13 (SEQ. ID. NO.:11), -190 to +6 (SEQ. I.D. NO.:12), or -190 to +5 (SEQ. ID. NO.:13) are also operative and useful. Non-human homologues include any cyclin Al promoter sequence of non-human origin that functions in a vertebrate stem cell type 30 of interest. Another preferred embodiment of a cyclin Al promoter is an operative derivative of 20 WO 00/29602 PCT/US99/08277 SEQ. ID. NO:2, or of any operative fragment of SEQ. ID. NO.:2 or non-human homologue thereof, in which the codon of the first translational start site is changed to another codon sequence, other than ATT, that is also not recognized as a translational start site; another preferred cyclin Al promoter is a derivative of SEQ. ID. NO.:2 with the codon of the first 5 translational start site deleted altogether. Other operative derivatives include cyclin Al promoter sequences containing a mutation, polymorphism, or variant allele with respect to any nucleotide position of SEQ. ID. NO.:2 that does not eliminate promoter activity. Similar to promoters in other cell cycle regulatory genes (B. Henglein et al., Proc. Natl. Acad. Sci. (USA) 91:5490-94 [1994]; A. Hwang et al., J. Biol. Chem. 270:28419-24 10 [1995]; E.W. Lam et al., Oncogene 7:1885-90 [1992]), the cyclin Al promoter does not possess a TATA-box motif. The nucleotides surrounding the transcriptional start site are likely to function as an initiator. The cyclin Al promoter region contains multiple binding sites for transcription factor including GC boxes, Myb, and E2F sites. The upstream region contains a GC rich region with multiple Spl binding sites that 15 are essential for transcription from the cyclin Al promoter. In contrast, predicted GC boxes in the cyclin A2 promoter are located more than 120 bp upstream of the transcriptional start site and these have not been shown to be essential for gene expression. GC boxes and the SpI family transcription factors are important in the regulation of expression from the cyclin Al promoter. Six GC boxes are found in the first 200 bp upstream of the transcription start site. 20 Omitting the four GC boxes between -112 and -37 almost completely abrogates promoter activity. Among GC boxes Nos. 1-4, the two closest to the transcriptional start sites are most critical. Of GC boxes Nos. 3 and 4, only one of these is necessary for a basal level of transcriptional activity of the promoter. Spl, the main activating factor of the SpI family, and Sp3 can bind to GC boxes Nos. 25 1 + 2 and 3 + 4. Analysis of these fragments in insect cells demonstrates that Spl reconstitutes cyclin Al promoter activity in all fragments that involve the GC boxes Nos. 1-4. Spi (or at least a member of the Spl family) is required for cyclin Al promoter activity through interaction with elements located between -112 and -37. Repression is likely to be accomplished by Sp3 and an as yet unidentified repressor mechanism that does not depend 30 on E2F, CDE or CHR elements. The DNA of animal cells is subject to methylation at the 5' carbon position of the 21 WO 00/29602 PCT/US99/08277 cytidine bases of CpG dinucleotides. Unmethylated CpGs are found preferentially in transcriptionally active chromatin. (T. Naveh-Many et al., Active gene sequences are undermethylated, Proc. Natl. Acad. Sci. USA 78:4246-50 [1981]). Hypermethylation is associated with transcriptional repression. (R. Holliday, The inheritance ofepigenetic defects, 5 Science 238:163-70 [1987]). Tissue-specific expression from the cyclin Al promoter in male germ cells is seen irrespective of promoter methylation status. Even high levels of methylation do not inhibit cyclin Al promoter expression during spermatogenesis. In contrast, expression from the cyclin Al promoter in somatic tissues has been observed only in a transgenic mouse line that 10 does not methylate the cyclin Al promoter. This is evidence that the effects of methylation on gene expression are tissue-specific and can differ between somatic and germ cells. High in vivo expression levels of cyclin Al in mice and healthy humans are restricted to germ cells. (R. Yang et al. [1997]; Sweeney et al. [1996]). For an unknown reason, cyclin Al is also frequently expressed at high levels in acute myeloid leukemia (R. Yang et al. 15 [1997]; R. Yang et al., Cyclin A] expression in leukemia and normal hematopoietic cells. Blood 93:2067-74 [1999]). Chromatin structure and probably changes in the methylation pattern contribute to tissue-specific expression. The cyclin Al promoter is highly GC rich and bears a CpG island that extends over several hundred base pairs and ends about 50 base pairs upstream of the main transcriptional start site. When the methylation pattern of the CpG 20 dinucleotides in the critical parts of the promoter was analyzed using bisulfite sequencing, as described in Example 22 below, a high degree of CpG methylation was observed in somatic, adherent cell lines but not in cyclin Al -expressing leukemia cell lines. Hypomethylation in leukemic cell lines is clearly restricted to the CpG island since a CpG at +114 outside of the CpG island was found to be completely methylated in all cell lines tested. 25 Therefore, for the purposes of obtaining selectable transgenic stem cells in accordance with the present method, silencing of expression from the cyclin Al promoter in stem cell types other than germ cells is preferably prevented by flanking the promoter sequence and the reporter gene with insulator elements. For example, by including double copies of the 1.2 kb chicken P-globin insulator element 5' to the cyclin Al promoter sequence and 3' to the 30 reporter protein gene in the present DNA construct, methylation will be substantially prevented at CG dinucleotide sites within the CpG island of the cyclin Al promoter sequence 22 WO 00/29602 PCT/US99/08277 and thus expression of the reporter gene occurs within stem cell types other than germ cells. (M.J. Pikaart et al., Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators, Genes Dev. 12:2852-62 [ 1998]; Chung et al., DNA sequence which acts as a chromatin insulator element to protect 5 expressed genes from cis-acting regulatory sequences in mammalian cells, U.S. Patent No. 5,610,053). Alternatively, when the method of obtaining selectable transgenic stem cells is practiced to select stem cells grown in vitro, inhibitors of histone deacetylation and DNA methylation, such as trichostatin A or sodium butyrate, can be included in the culture medium 10 to prevent silencing of reporter expression from the cyclin Al promoter in a wide variety of cultured stem cells. (M.J. Pikaart et al. [1998]). Suppression of methylation of the cyclin Al promoter sequence can sometimes cause expression from a cyclin Al promoter in kidney podocytes or in B-cells. Consequently, in applications in which selectable kidney stem cells are of interest, in accordance with the 15 present method of obtaining selectable transgenic stem cells, fluorescent or luminescent podocytes that express a reporter gene from a cyclin Al promoter are easily distinguished from fluorescing or light-emitting transgenic kidney stem cells by the distinct podocyte morphology (including protruding pedicels). In applications in which hematopoietic stem cells are of interest, fluorescent or luminescent B-cells are distinguished from transgenic 20 hematopoietic stem cells by additionally using a B-cell-specific antibody conjugated to a fluorescent label that fluoresces or emits at a different wavelength from that of the reporter protein expressed as a result of cyclin Al-promoted transcription. For example, phycoerythricin-conjugated monoclonal antibodies against B-cell-specific surface epitopes can be applied to a cell population sample from bone marrow to distinguish B-cells from 25 transgenic hematopoietic stem cells. Three potential binding sites for Myb proteins are present within 100 bp of the transcription start sites of the cyclin Al gene, located starting at -66, -27, and +2. (Fig. 3). Binding of c-myb protein occurs at the sites starting at -27 and +2, and c-myb protein transactivates expression from the human cyclin Al promoter, as described in Example 23. 30 In contrast, no consensus myb sites have been found for either the murine or human cyclin A2 promoter ( X. Huet et al., Molecular & Cellular Biology 16:3789-98 [1996]). 23 WO 00/29602 PCT/US99/08277 Similar to the cyclin A2 gene, two potential binding sites for transcription factor E2F are downstream of the transcriptional start site of cyclin Al. These E2F sites are not required for repression of cyclin A2 transcription in the G1 phase. (J. Zwicker et al. (1995) EMBO Journal 14, 4514-4522; X. Huet et al. [1996]). Likewise, the introduction of mutations in 5 these sites in the cyclin Al promoter does not alter the regulation of expression. Further evidence that these E2F sites are not relevant for regulation was shown using a 3 deletion ( 190 to +13) that showed cell cycle regulation in vivo similar to the constructs containing both E2F sites (data not shown). Likewise, a 6-bp sequence that resembles the CDE of the human cyclin A2 gene was found in an antisense direction at position -19 to -24 (TCGCGG; SEQ. 10 ID. NO.:32) of the cyclin Al promoter. No significant differences in cell cycle regulation were found when these nucleotides were mutated (Fig. 9). This is consistent with the finding that these elements need to be in a 5' to 3' orientation to be functional (J.Zwicker et al. [1995]; N. Liu et al., Oncogene 16:2957-63 [1998]; N. Liu et al., Nucleic Acids Res. 25: 4915-20 [1997]). 15 The present invention relates to a method of obtaining a selectable transgenic stem cell from a vertebrate. The method involves transfecting a male germ cell or germ cell precursor with a transfection mixture, as described herein, that includes a polynucleotide, comprising a stem cell-specific promoter sequence, for example, a human or other homologous vertebrate cyclin Al promoter sequence, or an operative fragment thereof, operatively linked to a gene 20 encoding a fluorescent or light-emitting reporter protein, oriented so as to comprise a transcriptional unit. A polynucleotide containing the operatively linked stem cell-specific promoter and reporter gene, is incorporated in to the genome of a transfected male germ cell, or precursor, and can be transmitted to progeny after breeding, where it operates in stem cells of the progeny in vivo, such that in a cell population, taken from a progeny vertebrate's tissue 25 or viewed in situ, stem cells differentially express the reporter gene compared to non-stem cells. Thus, these stem cells are readily selectable from the population of non-stem cells present in the tissue. Types of stem cells for which the method is useful include pluripotent, multipotent, bipotent, or monopotent stem cells, which includes male or female germ cells or stem cells related to any tissue of the vertebrate including, but not limited to, spermatogonial, 30 embryonic, osteogenic, hematopoietic, granulopoietic, sympathoadrenal, mesenchymal, epidermal, neuronal, neural crest, 0-2A progenitor, brain, kidney, pancreatic, liver or cardiac 24 WO 00/29602 PCT/US99/08277 stem cells. And the present invention is also directed to a selectable transgenic stem cell, of any type, obtained by the method. Preferred reporter genes encode fluorescent proteins including Green Fluorescent Protein (or EGFP), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, 5 such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of ultra-violet or other light. Another reporter gene suitable for some applications is a gene encoding a protein that can enzymatically lead to the emission of light from a substrate(s); for purposes of the present invention, such a protein is a "light-emitting protein." For example, a light-emitting protein includes proteins such as luciferase or 10 apoaequorin. In particular applications involving a transfected cell that expresses additional xenogeneic genes from any promoter, this expression may be linked to a reporter gene that encodes a different fluorescent or light-emitting protein from the reporter gene linked to the cyclin Al promoter. Thus, multiple reporters fluorescing or emitting at different wavelengths 15 can be chosen and cell selections based on the expression of multiple traits can be made. The selectable transgenic stem cells may be sorted, isolated or selected from non-stem cells with the aid of, for example, a FACS scanner set at the appropriate wavelength(s). Alternatively, they are isolated or selected manually from non-stem cells using conventional microscopic technology. It is an advantage of the present method of obtaining selectable transgenic stem 20 cells that it allows stem cells to be selected or isolated from non-embryonic tissue. The invention also relates to a nucleic acid construct comprising a human cyclin Al promoter sequence in accordance with the present invention, or an operative fragment thereof. In a preferred embodiment for use in the method of obtaining a selectable transgenic stem cell, the cyclin Al promoter is operatively linked to a DNA having a nucleotide sequence encoding 25 a fluorescent protein or a light emitting protein. Other preferred embodiments employ a xenogeneic nucleic acid encoding any desired product or trait. For purposes of the present invention, "operatively linked" means that the promoter sequence, is located directly upstream from the coding sequence and that both sequences are oriented in a 5' to 3' manner, such that transcription could take place in vitro in the presence of all essential enzymes, transcription 30 factors, co-factors, activators, and reactants, under favorable physical conditions, e.g., suitable pH and temperature. This does not mean that, in any particular cell, conditions will favor 25 WO 00/29602 PCT/US99/08277 transcription. For example, transcription from a cyclin Al promoter is not favored in most differentiated cell types in transgenic animals. The present invention also relates to a transgenic vertebrate cell containing the nucleic acid construct of the present invention, regardless of the method by which the construct was 5 introduced into the cell. The present invention also relates to transgenic non-human vertebrates comprising such cells. The present invention also relates to a kit for transfecting a male vertebrate's germ cells, which is useful for obtaining selectable transgenic stem cells. The kit is a ready assemblage of materials for facilitating the transfection of a vertebrate male germ cell. A kit 10 of the present invention contains a transfecting agent, as described above, and a polynucleotide that includes a stem cell-specific promoter sequence operatively linked to a DNA sequence encoding a fluorescent or light-emitting protein, together with instructions for using the components effectively. Preferably, the kit includes a nucleic acid construct of the present invention. Optionally, the kit can include an immunosuppressing agent, such as 15 cyclosporin or a corticosteroid, and/or an additional nucleotide sequence encoding for the expression of a desired trait. The materials or components assembled in the kit are provided to the practitioner stored in any convenient and suitable way that preserves their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. 20 This invention also relates to a method for the isolation of spermatogonia, comprising obtaining spermatogonia from a mixed population of testicular cells by extruding the cells from the seminiferous tubules and gentle enzymatic disaggregation. The spermatogonia or stem cells which are to be genetically modified, may be isolated from a mixed cell population by a novel method including the utilization of a promoter sequence, which is only active in 25 stem cells, such as human cyclin Al promoter, or in cycling spermatogonia stem cell populations, for example, B-Myb or a spermotogonia specific promoter, such as the c-kit promoter region, c-raf- 1 promoter, ATM (ataxia-telangiectasia) promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI (from fragile X site) promoter, linked to a reporter 30 construct, for example, a construct comprising a gene encoding Green Fluorescent Protein (or EGFP), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as 26 WO 00/29602 PCT/US99/08277 phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave lengths of light. These unique promoter sequences drive the expression of the reporter construct only in the cycling spermatogonia. The spermatogonia, thus, are the only cells in the mixed population which will express the reporter construct(s) and they, thus, may be 5 isolated on this basis. In the case of a fluorescent reporter construct, the cells may be sorted with the aid of, for example, a FACS set at the appropriate wavelength(s) or they may be selected by chemical methods. The method of the invention is suitable for application to a variety of vertebrate animals, all of which are capable of producing gametes, i.e. sperm or ova. Thus, in 10 accordance with the invention novel genetic modification(s) and/or characteristic(s) may be imparted to animals, including mammals, such as humans, non-human primates, for example simians, marmosets, domestic agricultural (farm) animals such as sheep, cows, pigs, horses, particularly race horses, marine mammals, feral animals, felines, canines, pachyderms, rodents such as mice and rats, gerbils, hamsters, rabbits, and the like. Other animals include fowl such 15 as chickens, turkeys, ducks, ostriches, emus, geese, guinea fowl, doves, quail, rare and ornamental birds, and the like. Of particular interest are endangered species of wild animal, such rhinoceros, tigers, cheetahs, certain species of condor, and the like. The present invention is also related to a transgenic non-human vertebrate comprising a selectable transgenic stem cell in accordance with the present invention. Broadly speaking, 20 a "transgenic" vertebrate animal is one that has had foreign DNA permanently introduced into its cells. The foreign gene(s) which (have) been introduced into the animal's cells is (are) called a "transgene(s)". The present invention is applicable to the production of transgenic animals containing xenogeneic, i.e., exogenous, transgenic genetic material, or material from a different species, including biologically functional genetic material, in its native, 25 undisturbed form in which it is present in the animal's germ cells. In other instances, the genetic material is "allogeneic" genetic material, obtained from different strains of the same species, for example, from animals having a "normal" form of a gene, or a desirable allele thereof. Also the gene may be a hybrid construct consisting of promoter DNA sequences and DNA coding sequences linked together. These sequences may be obtained from different 30 species or DNA sequences from the same species that are not normally juxtaposed. The DNA 27 WO 00/29602 PCT/US99/08277 construct may also contain DNA sequences from prokaryotic organisms, such as bacteria, or viruses. In one preferred embodiment, the transfected germ cells of the transgenic animal have the non-endogenous (exogenous) genetic material integrated into their chromosomes. This is 5 what is referred to as a "stable transfection". This is applicable to all vertebrate animals, including humans. Those skilled in the art will readily appreciate that any desired traits generated as a result of changes to the genetic material of any transgenic animal produced by this invention are inheritable. Although the genetic material was originally inserted solely into the germ cells of a parent animal, it will ultimately be present in the germ cells of future 10 progeny and subsequent generations thereof. The genetic material is also present in all other cells of the progeny, including somatic cells and all non-stem cells, of the progeny. This invention also encompasses progeny resulting from breeding of the present transgenic animals. The transgenic animals bred with other transgenic or non-transgenic animals of the same species will produce some transgenic progeny, which should be fertile. This invention, 15 thus, provides animal line(s) which result from breeding of the transgenic animal(s) provided herein, as well as from breeding their fertile progeny. "Breeding", in the context of this patent, means the union of male and female gametes so that fertilization occurs. Such a union may be brought about by natural mating, i.e. copulation, or by in vitro or in vivo artificial means. Artificial means include, but are not 20 limited to, artificial insemination, in vitro fertilization, cloning and embryo transfer, intracytoplasmic spermatozoal microinjection, cloning and embryo splitting, and the like. However, others may also be employed. The transfection of mature male germ cells may be also attained utilizing the present technology upon isolation of the cells from a vertebrate, as is known in the art, and 25 exemplified in Example 10. The thus isolated cells may then be transfected ex vivo (in vitro), or prepared for cryostorage, as described in Example 11. The actual transsection of the isolated testicular cells may be accomplished, for example, by isolation of a vertebrate's testes, decapsulation and teasing apart and mincing of the seminiferous tubules. The separated cells may then be incubated in an enzyme mixture comprising enzymes known for 30 gently breaking up the tissue matrix and releasing undamaged cells such as, for example, pancreatic trypsin, collagenase type I, pancreatic DNAse type I, as well as bovine serum 28 WO 00/29602 PCT/US99/08277 albumin and a modified DMEM medium. The cells may be incubated in the enzyme mixture for a period of about 5 min to about 30 min, more preferably about 15 to about 20 min, at a temperature of about 33 C to about 37'C, more preferably about 36 to 37 0 C. After washing the cells free of the enzyme mixture, they may be placed in an incubation medium such as 5 DMEM, and the like, and plated on a culture dish. Any of a number of commercially available transfection mixtures may be admixed with the polynucleotide encoding a desire trait or product for transfection of the cells. The transfection mixture may then be admixed with the cells and allowed to interact for a period of about 2 hrs to about 16 hrs, preferably about 3 to 4 hrs, at a temperature of about 33 C to about 37'C, preferably about 36'C to 10 37 C, and more preferably in a constant and/or controlled atmosphere. After this period, the cells are preferably placed at a lower temperature of about 33 C to about 34'C, preferably about 30-35 C for a period of about 4 hrs to about 20 hrs, preferably about 16 to 18 hrs. Other conditions which do not deviate radically from the ones described may also be utilized as an artisan would know. 15 The present method is applicable to the field of gene therapy, since it permits the introduction of genetic material encoding and regulating specific genetic traits. Thus, in the human, for example, by treating parents it is possible to correct many single gene disorders which otherwise might affect their children. It is similarly possible to alter the expression of fully inheritable disorders or those disorders having at least a partially inherited basis, which 20 are caused by interaction of more than one gene, or those which are more prevalent because of the contribution of multiple genes. This technology may also be applied in a similar way to correct disorders in animals other than human primates. In some instances, it may be necessary to introduce one or more "gene(s)" into the germ cells of the animal to attain a desired therapeutic effect, as in the case where multiple genes are involved in the expression 25 or suppression of a defined trait. In the human, examples of multigenic disorders include diabetes mellitus caused by deficient production of, or response to, insulin, inflammatory bowel disease, certain forms of atheromatus cardiovascular disease and hypertension, schizophrenia and some forms of chronic depressive disorders, among others. In some cases, one gene may encode an expressible product, whereas another gene encodes a regulatory 30 function, as is known in the art. Other examples are those where homologous recombinant methods are applied to repair point mutations or deletions in the genome, inactivation of a 29 WO 00/29602 PCT/US99/08277 gene causing pathogenesis or disease, or insertion of a gene that is expressed in a dominant negative manner, or alterations of regulating elements such as gene promoters, enhancers, the untranslated tail region of a gene, or regulation of expansion of repeated sequences of DNA which cause such diseases as Huntingdon's chorea, Fragile-X syndrome and the like. 5 A specific reproductive application of the present method is to the treatment of animals, particularly humans, with disorders of spermatogenesis. Defective spermatogenesis or spermiogenesis frequently has a genetic basis, that is, one or several mutations in the genome may result in failure of production of normal sperm cells. This may happen at various stages of the development of germ cells, and may result in male infertility or sterility. 10 The present invention is applicable, for example, to the insertion or incorporation of nucleic acid sequences into a recipient's genome and, thereby, establish spermatogenesis in the correction of oligozoospermia or azoospermia in the treatment of infertility. Similarly, the present methods are also applicable to males whose subfertility or sterility is due to a motility disorder with a genetic basis. 15 The present method is additionally applicable to the generation of transgenic animals expressing agents which are of therapeutic benefit for use in human and veterinary medicine or well being. Examples include the production of pharmaceuticals in domestic cows' milk, such as factors which enhance blood clotting for patients with types of haemophilia, or hormonal agents such as insulin and other peptide hormones. 20 The present method is further applicable to the generation of transgenic animals of a suitable anatomical and physiological phenotype for human xenograft transplantation. Transgenic technology permits the generation of animals which are immune-compatible with a human recipient. Appropriate organs, for example, may be removed from such animals to allow the transplantation of, for example, the heart, lung and kidney. 25 In addition, germ cells transfected in accordance with this invention may be extracted from the transgenic animal, and stored under conditions effective for later use, as is known in the art. Storage conditions include the use of cryopreservation using programmed freezing methods and/or the use of cryoprotectants, and the use of storage in substances such as liquid nitrogen. The germ cells may be obtained in the form of a male animal's semen, or separated 30 spermatozoa, or immature spermatocytes, or whole biopsies of testicular tissue containing the primitive germ cells. Such storage techniques are particularly beneficial to young adult 30 WO 00/29602 PCT/US99/08277 humans or children, undergoing oncological treatments for such diseases such as leukemia or Hodgkin's lymphoma. These treatments frequently irreversibly damage the testicle and, thus, render it unable to recommence spermatogenesis after therapy by, for example, irradiation or chemotherapy. The storage of germ cells and subsequent testicular transfer allows the 5 restoration of fertility. In such circumstances, the transfer and manipulation of germ cells as taught in this invention are accomplished, but transfection is generally not relevant or needed. In species other than humans, the present techniques are valuable for transport of gametes as frozen germ cells. Such transport will facilitate the establishment of various valued livestock or fowl, at a remote distance from the donor animal. This approach is also 10 applicable to the preservation of endangered species across the globe. The method of obtaining selectable transgenic stem cells, the selectable transgenic stem cells, the transgenic non-human vertebrates and vertebrate semen, and the nucleic acid contructs and kits, in accordance with the present invention, are valuable tools in the study of cellular differentiation and development and in developing new therapies for diseases 15 related to cell differentiation, such as cancer, or for the regeneration of tissues after traumatic injuries. The present invention is valuable in identifying cell lineages before full differentiation to facilitate modification and/or engineering of specific tissues in vitro for their subsequent transplantation in the treatment of disease or trauma. It is an advantage of the present method of obtaining selectable transgenic stem cells that it allows stem cells to be 20 selected or isolated from non-embryonic tissue, thus avoiding potential ethical and legal problems associated with the use of embryonic tissue. It is a further advantage that in accordance with the present invention, selectable transgenic stem cells can be selected and analyzed whether grown in vivo (i.e., in the whole organism) or in vitro. The invention will now be described in greater detail by reference to the following 25 non-limiting examples. The pertinent portions of the contents of all references, and published patent applications cited throughout this patent necessary for enablement purposes are hereby incorporated by reference. EXAMPLES In Vivo and In Vitro Adenovirus-enhanced Transferrin-polylysine-mediated Delivery 31 WO 00/29602 PCT/US99/08277 of Green Fluorescent Protein Reporter Gene to Testicular Cells and Expression The adenovirus enhanced transferrin-polylysine-mediated gene delivery system has been described and patented by Curiel et al. (D.T. Curiel et al. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery, PNAS USA 88: 8850-8854 (1991). The 5 delivery of DNA depends upon endocytosis mediated by the transferrin receptor (Wagner et al., Transferrin-polycation conjugates as carriers for DNA uptake into cells, Proc. Natl. Acad. Sci. (USA) 87:3410-3414 (1990). In addition this method relies on the capacity of adenoviruses to disrupt cell vesicles, such as endosomes and release the contents entrapped therein. This system can enhance the gene delivery to mammalian cells by as much as 2,000 10 fold over other methods. The gene delivery system employed for the in vivo and in vitro experiments was prepared as shown in examples below. Example 1: Preparation of Transferrin-poly-L-Lysine Complexes Human transferrin was conjugated to poly (L-lysine) using EDC (1-ethyl-3-(3 15 dimethyl aminopropyl carbodiimide hydrochloride) (Pierce), according to the method of Gabarek and Gergely (Gabarek & Gergely, Zero-length cross-linking procedure with the use of active esters, Analyt. Biochem 185 : 131 (1990)). In this reaction, EDC reacts with a carboxyl group of human transferrin to form an amine-reactive intermediate. The activated protein was allowed to react with the poly (L-lysine) moiety for 2 hrs at room temperature, 20 and the reaction was quenched by adding hydroxylamine to a final concentration of 10 mM. The conjugate was purified by gel filtration, and stored at -20'C. Example 2: Preparation of DNA for In Vivo Trasfection The Green Lantern-1 vector (Life Technologies, Gibco BRL, Gaithersberg, MD) is a reporter construct used for monitoring gene transfection in mammalian cells. It consists of 25 the gene encoding the Green Fluorescent Protein (GFP) driven by the cytomegalovirus (CMV) immediate early promoter. Downstream of the gene is a SV40 polyadenylation signal. Cells transfected with Green Lantern-I fluoresce with a bright green light when illuminated with blue light. The excitation peak is 490 nm. 32 WO 00/29602 PCT/US99/08277 Example 3: Preparation of Adenoviral Particles Adenovirus d1312, a replication-incompetent strain deleted in the Ela region, was propagated in the Ela trans-complementing cell line 293 as described by Jones and Shenk (Jones and Shenk, PNAS USA (1979) 79: 3665-3669). A large scale preparation of the virus 5 was made using the method of Mittereder and Trapnell (Mittereder et al., "Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy", J. Urology, 70: 7498 7509 (1996)). The virion concentration was determined by UV spectroscopy, 1 absorbance unit being equivalent to 10 viral particles /ml. The purified virus was stored at -70 C. Example 4: Formation of Transferrin-poly-L Lysine-DNA-Viral Complexes 10 6 ptg transferrin-polylysine complex from Example 1 were mixed in 7.3 x 107 adenovirus d1312 particles prepared as in Example 3, and then mixed with 5 ug of the Green Lantern DNA construct of Example 2, and allowed to stand at room temperature for 1 hour. About 100 ul of the mixture were drawn up into a micropipette, drawn on a pipette puller, and slightly bent on a microforge. The filled micropipette was then attached to a picopump 15 (Eppendorf), and the DNA complexes were delivered under continuous pressure, in vivo to mice as described in Example 6. Controls were run following the same procedure, but omitting the transferrin-poly-lysine-DNA-vira complexes from the administered mixture. Example 5: Comparison of Adenovirus-enhanced Transferrin-polylysine 20 & Lipofectin Mediated Transfection Efficiency The conjugated adenovirus particle complexed with DNA were tested on CHO cells in vitro prior to in vivo testing. For these experiments a luciferase reporter gene was used due to the ease of quantifying luciferase activity. The expression construct consists of a reporter gene encoding luciferase, is driven by the CMV promoter (Invitrogen, Carlsbad, CA 92008). 25 CHO cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum. For gene transfer experiments CHO cells were seeded into 6 cm tissue culture plates and grown to about 50% confluency (5x10 5 cells). Prior to transfection the medium was aspirated and replaced with serum free DMEM. Cells were either transfected with transferrin polylysine-DNA complexes or with lipofectin DNA aggregates. For the transferrin 33 WO 00/29602 PCTIUS99/08277 polylysine mediated DNA transfer, the DNA-adenovirus complexes were added to the cells at a concentration of 0.05-3.2 x 104 adenovirus particles per cell. Plates were returned to the 5% CO 2 incubator for 1 hour at 37'C. After 1 hour 3 ml of complete media was added to the wells and the cells were allowed to incubate for 48 hours before harvesting. The cells were 5 removed from the plate, counted and then lysed for measurement of luciferase activity. For cells transfected by lipofectin, 1 tg of CMV-luciferase DNA was incubated with 17pl of Lipofectin (Life Technologies). The DNA-lipofectin aggregates were added to the CHO cells and allowed to incubate at 37 0 C at 5% CO 2 for 4 hours. Three mls of complete medium was added then to the cells and they were allowed to incubate for 48 hours. The cells 10 were harvested, counted and lysed for luciferase activity. The luciferase activity was measured by a luminometer. The results obtained are shown in Table 1. The data included in Table 1 below show that the adenovirus-enhanced transferrin polylysine gene delivery system is 1,808 fold more efficient than lipofection for transfection of CHO cells. 15 Table 1: Comparison of Lipofection & Adenovirus Enhanced Transferrin-polylysine Transfection of CHO Cells Sample Treatment L u c i f e r a s e Activity (RLU) 20 1 1x10 7 particles + 6ug CMV-Luc 486 2 2.5 x 107 particles + 6ug CMV-Luc 1,201 3 5.0 x 107 particles + 6ug CMV-luc 11,119 4 1 x 10, particles + 6ug CMV-Luc 2,003,503 5 Lipofection 1,108 25 6 Unmanipulated cells 155 Example 6: In Vivo Delivery of DNA to Animal's Germ Cells via Tranferrin-L-lysine-DNA-Viral Complexes The CMV-EGFP (Gibco-BRL, Life Technologies, Gaithersburg, MD 20884) 30 DNA-transferrin-polylysine viral complexes, prepared as described in Example 4 above, were delivered into the seminiferous tubules of three (3)-week-old B6D2F 1 male mice. The DNA delivery by transferrin receptor-mediated endocytosis is described by Schmidt et al. and 34 WO 00/29602 PCT/US99/08277 Wagner et al. (Schmidt et al., Cell 4: 41-51 (1986); Wagner, E., et al. PNAS (1990), (USA) 81: 3410-3414 (1990)). In addition, this delivery system relies on the capacity of adenoviruses to disrupt cell vesicles, such as endosomes and release the contents entrapped therein. The transfection efficiency of this system is almost 2,000 fold higher than 5 lipofection. The male mice were anesthetized with 2% Avertin ( 100% Avertin comprises 10 g 2,2,2-tribromoethanol (Aldrich) and 10 ml t-amyl alcohol (Sigma), and a small incision made in their skin and body wall, on the ventral side of the body at the level of the hind leg. The animal's testis was pulled out through the opening by grasping at the testis fat pad with 10 forceps, and the vas efferens tubules exposed and supported by a glass syringe. The EGFP DNA-transferrin-polylysine viral complexes were injected into a single vasa efferentia using a glass micropipette attached to a hand held glass syringe or a pressurized automatic pipettor (Eppendorf), and Trypan blue added to visualize the entry of the mixture into the seminiferous tubules. The testes were then placed back in the body cavity, the body wall was sutured, the 15 skin closed with wound clips, and the animal allowed to recover on a warm pad. Example 7: Detection of DNA and Transcribed Message Nine (9) days after delivery of the genetic material to the animals' testis, two of the animals were sacrificed, their testes removed, cut in half, and frozen in liquid nitrogen. The DNA from one half of the tissues, and the RNA from the other half of the tissues were 20 extracted and analyzed. (a) Detection of DNA The presence of DNA encoding enhanced green fluorescent protein (EGFP DNA) in the extracts was tested 9 days after administration of the transfection mixture using the polymerase chain reaction, and EGFP specific oligonucleotides. EGFP DNA was present in 25 the testes of the animals that had received the DNA complexes, but was absent from sham operated animals. (b) Detection of RNA 35 WO 00/29602 PCT/US99/08277 The presence of CMV-EGFP mRNA was assayed in the testes of experimental animals as follows. RNA was extracted from injected, and non-injected testes, and the presence of the EGFP messages was detected using reverse transcriptase PCR (RTPCR) with EGFP specific primers. The EGFP message was present in the injected testes, but not in the control testes. 5 Thus, the DNA detected above by PCR analysis is, in fact, episomal EGFP DNA, or EGFP DNA which has integrated into the chromosomes of the animal. The transfected gene was being expressed. Northern blot analysis was also done to confirm transcription regulated by the human cyclin Al promoter. Total RNA was prepared from tissues using a RNA tissue preparation 10 kit (Qiagen). Polyadenylated RNA was prepared by passage over an oligo(dT)-cellulose column. The RNA is polyoxylated and applied to 1.5% Agarose gel. After electrophoresis the RNA is transferred to nitrocelullose paper and hybridized with a cyclin Al cDNA riboprobe. After hybridization the membrane was washed twice with lx SSC at 60'C for 1 hour. The washed membrane was exposed to X-ray film. 15 Example 8: Expression of Non-endogenous DNA Two males, one having received an injection with the EGFP transfection mixture and a control to whom only surgery was administered, were sacrificed 4 days after injection, and their testes excised, and fixed in 4% paraformaldehyde for 18 hours at 4 C. The fixed testis was then placed in 30% sucrose in PBS with 2 mM MgCl 2 for 18 hours at 4'C, embedded in 20 OCT frozen on dry ice, and sectioned. When the testes of both animals were examined with a confocal microscope with fluorescent light at a wavelength of 488 nM, bright fluorescence was detected in the tubules of the EGFP-injected mice, but not in the testes of the controls. Many cells within the seminferous tubules of the EGFP-injected mouse showed bright fluorescence, which evidences that they were expressing Green Fluorescent Protein. 25 Example 9: Generation of Offspring from Normal Matings EGFP-transfected males were mated with normal females. The females were allowed to complete gestation, and the pups to be born. The pups (Fl offspring or progeny) were screened for the presence of the novel genetic material(s). 36 WO 00/29602 PCT/US99/08277 Example 10: In Vitro Transfection of Testicular Cells Cells were isolated from the testes of three 10-day-old mice. The testes were decapsulated and the seminiferous tubules were teased apart and minced with sterile needles. The cells were incubated in enzyme mixture for 20 minutes at 37'C. The enzyme mixture was 5 made up of 10 mg bovine serum albumin (embryo tested), 50 mg bovine pancreatic trypsin type III, Clostridium collagenase type I, 1 mg bovine pancreatic DNAse type I in 10 mls of modified HTF medium (Irvine Scientific, Irvine, CA). The enzymes were obtained from Sigma Company (St. Louis, Missouri 63178). After digestion, the cells were washed twice by centrifugation at 500 x g with HTF medium and resuspended in 250pl HTF medium. The 10 cells were counted, and 0.5 x 106 cells were plated in a 60mm culture dish in a total volume of 5ml DMEM (Gibco-BRL, Life Technologies, Gaithesburg, MD 20884). A transfection mixture was prepared by mixing 5 pg Green Lantern DNA (Gibco-BRL, Life Technologies, Gaithesburg, MD 20884) with 20A Superfect (Qiagen, Santa Clarita, CA 91355) and 150p1 DMEM. The transfection mix was added to the cells and they were allowed to incubate for 15 3 hours at 37'C, 5% CO 2 The cells were transferred to a 33 C incubator and incubated overnight. The following morning the cells were assessed for transfection efficiency by counting the number of fluorescent cells. In this experiment the transfection efficiency was 90% (Figure not shown). The testicular cells transfected with Green Lantern viewed with Nomaski 20 optics x20 show the same cells viewed with FITC. Nearly all the cells were fluorescent, which is confirmation of their successful transfection. The cells were injected into the testis via the vasa efferentia using a micropipette. 3 x 10' cells in a total volume of 50il were used for the injection. The cells were mixed with Trypan blue prior to the injection. Three adult mice were injected with transfected cells. The 25 Balb/cByJ recipient mice had been irradiated 6 weeks prior to the injection with 800 Rads of gamma irradiation. One mouse became sick and was sacrificed 48 hours after the injection. The testes from this mouse were dissected, fixed and processed for histology. The two remaining males were bred with normal females as shown. After 4 months pups were born. Litters are currently being screened for the integration of the transgene. 30 Example 11: Preparation of a Cell Suspension from Testicular Tissue for Cryopreservation 37 WO 00/29602 PCT/US99/08277 A cell suspension was prepared from mice of different ages as described below. Group I: 7-10 day olds Group II: 15-17 day olds Group III: 24-26 day olds 5 The mice's testes were dissected, placed in phosphate buffered saline (PBS) decapsulated, and the seminiferous tubules were teased apart. Seminiferous tubules from groups I and II were transferred to HEPES buffered culture medium (D-MEM) (Gibco-BRL, Life Technologies, Gaithesburg, MD 20884) containing lmg/ml Bovine serum albumin (BSA) (Sigma, St. Louis, MO 63178) and Collagenase Type I (Sigma) for the removal of 10 interstitial cells. After a 10 minute incubation at 33'C, the tubules were lifted into fresh culture medium. This enzymatic digestion was not carried out on the testes from group I because of their fragility. The tubules from group II and III mice or the whole tissue from group I mice were transferred to a Petri dish with culture medium and were cut into 0.1-1mm pieces using a 15 sterile scalpel and needle. The minced tissue was centrifuged at 500 x g for 5 minutes and the pellet was resuspended in lml of enzyme mix. The enzyme mix was made up in D-DMEM with HEPES (Gibco-BRL) and consisted of lmg/ml bovine serum albumin (BSA) (Sigma, embryo tested), 1mg/ml collagenase I (Sigma) and 5 mg/ml bovine pancreatic trypsin (Sigma) and 0.lmg/ml deoxyribonuclease I (DN-EP, Sigma). The tubules were incubated in enzyme 20 mix for 30 minutes at 33"C. After the incubation, lml of medium was added to the mix and the cells were centrifuged at 500 x g for 5 min. The cells were washed twice in medium by centrifugation and resuspension. After the final wash the cell pellet was resuspended in 250pl of culture medium and counted. Example 12: Cloning of the cyclin Al gene and construction of DNA constructs containing 25 cyclin Al-luciferase Cloning of the genomic fragment of the human cyclin Al. The cyclin Al gene was cloned by screening a genomic Fix II lambda library made from placenta (Stratagene) using the cyclin Al cDNA as a probe. (R. Yang et al. [1997]). Of the several phage clones obtained, one contained all the exons and included a 1.3 kb region upstream of the 5' end of the cDNA. A 30 2.2 kb NotI-Bam HI fragment from the 5' end of the gene was subcloned into the pRS316 38 WO 00/29602 PCT/US99/08277 cloning vector. The construct was further digested using Sma I; and three fragments were subcloned into PUC19. The fragments were sequenced in both directions using cycle sequencing and an automated sequencer (AB1373) or Sequenase 2.0 (Amersham). The positions and lengths of the introns were determined by PCR amplification of the entire cyclin 5 Al coding region with different primers. Subsequently, PCR products were either subcloned using pGEM-T-Easy (Promega) or directly sequenced using cycle sequencing. Boundaries of the -4.5 kb intron 2 were determined by direct sequencing of the lambda phage clone. Generation of cyclin Al -luciferase DNA constructs. The initial luciferase constructs were generated by PCR amplification of the pRS316 plasmid containing the 2.2 kb cyclin Al 10 fragment. A BglII site at the 5' end and a Bam HI site at the 3' end were introduced and the Pfu amplified fragment was cloned into the BgJII site of PGL3-Basic. The +144 fragment was generated to include the potential E2F site starting at + 139. (Figure 3). The ATG in the primer (the initiating codon for cyclin Al at nt. +127 to +129) was mutated to ATT to avoid the initiation of translation. All constructs were confirmed to have the correct sequence by 15 DNA sequencing. The 5' deletions were generated by exonuclease III treatment using Kpn I/Sac I digested PGL3-Basic containing the -1299 to +144 fragment and the Erase-a-base kit (Promega). The endpoints of the deletions were determined by sequencing. The -37 fragment was constructed by digesting the -190 to +144 containing PGL3-Basic with NaeI and Hind III and subsequent cloning of the 200 bp fragment into PGL3-Basic digested with Sma I and Hind 20 III. Cell culture and transfection. Hela cells were cultured in DMEM medium supplemented with 10% fetal calf serum (FCS) containing 100 U/ml Penicillin and 100 pg/mL Streptomycin. For transfection, 5 x 10' cells were seeded into 60 mm plates 16 hours before transfection. Transfection was carried out using lipofectAMINE (Gibco, Life Technology) according to the 25 manufacturer's protocol. Two pag of luciferase reporter plasmid was transfected together with 300 ng of a CMV-P-gal expression vector used for standardization. Cells were harvested and assayed for luciferase and p-galactosidase activity after 48 hours. All experiments were carried out in duplicate and were independently performed at least 3 times. Data of luciferase assays are shown as mean ± SEM of three independent experiments unless stated otherwise. 39 WO 00/29602 PCT/US99/08277 The Drosophila cell line S2 was obtained from ATCC and grown at room temperature in Schneider's insect cell medium (Gibco) supplemented with 10% FCS. Insect cells were transfected using Superfect (Qiagen). Briefly, 5x10 5 cells were seeded into 6 well plates and the superfect-DNA mixture was added dropwise. One pg of the luciferase reporter was 5 transfected with or without 100 ng of the Spl expression vector pAC-SpI which was a kind gift from Dr. E. Stanbridge (UC Irvine). Luciferase activity was analyzed after 48 hours. Luciferase values could not be standardized using p-galactosidase activity because the viral promoters in the available plasmids also depended strongly on Spl for adequate expression. All experiments were carried out in duplicate and independently performed at least 3 times. 10 Cell cycle dependent promoter activity. Hela cells were transfected using lipofectAMINE as described above. After transfection, cells were cultured in 0.1% FCS containing medium. After 16 h, medium was exchanged and cells were synchronized essentially as described. (D. Carbonaro-Hall et al., Oncogene 8:1649-59 [1993]). Cells were arrested in G, by serum starvation (0.1% FCS), in early S phase by aphidicolin (2,u/ml), and in S phase by aphidicolin 15 treatment and release into fresh medium 6 hours before harvest. Cells were arrested in G 2 /M phase by nocodazole (0.1 pg/ml). Appropriate synchronization was confirmed by DNA quantitation using flow cytometry and the experiments were performed at least three times. For the cell cycle release experiments, Hela cells were arrested using aphidicolin as described above but cells were harvested at the different time points. The time course experiments were 20 independently performed two times. RACE and primer extension. The rapid amplification of 5' cDNA ends (RACE) was performed using a 5' RACE system (Gibco). The procedure was performed as suggested in the manufacturer's protocol using RNA of the myeloid leukemia cell lines ML1 and U937. RNA was reversed transcribed using the primer 5'-CCC TCT CAG AAC AGA CAT ACA 25 (SEQ. ID. NO.: 14; positions +981 to +961 of the cDNA) and Superscript II reverse transcriptase (Gibco). Gene-specific cDNA was PCR-amplified using the gene-specific primer 5'-CTG ATC CAG AAT AAC ACC TGA (SEQ. ID. NO.:15; positions +460 to +440 of the cDNA) and the universal 5' RACE Abridged Anchor Primer 5'-GGC CAC GCG TCG ACT AGT ACG GGI IGG GII GGG IIG (SEQ. ID. NO.: 16; I=inosine). PCR-amplifications 30 from both RNA samples yielded a single band of about 450 bp. The entire PCR product was 40 WO 00/29602 PCT/US99/08277 phenol-chloroform extracted, precipitated using NH 4 ' acetate and finally cloned into pGEM-T Easy and sequenced. The primer extension assay was carried out by reverse transcription of 10ptg RNA (U937) using a 32 P-labeled primer 5'-CTC CTC CCA CCA GAC AGG A (SEQ. ID. NO.: 17) 5 corresponding to +95 to +76 on the cDNA. Hybridization was carried out overnight at 58 C. Superscript II was used for reverse transcription at 42 C for 50 minutes. Extension products were resolved on a 8% sequencing gel with a sequencing reaction being run in parallel. As negative controls, we used 10pg of t-RNA and a sample without RNA. Electrophoretic Mobility Shift Assays. Nuclear extracts from Hela cells were prepared as 10 described (A.M. Chumakov et al., Oncogene 8:3005-11 [1993]). For gel retardation experiments, 1 ng of 1 2 P- labeled double stranded oligonucleotides containing either GC boxes 1+2 (5'-CCT GCC CCG CCC TGC CCC GCC CAG CC; SEQ. ID. NO.: 18) or GC boxes 3+4 (5'-CCT TCC CCG CCC TGC CCC GCC CGG CCC; SEQ. ID. NO.:19) were incubated for 20 min at room temperature with 5 Mg of Hela nuclear extract. The final reaction contained: 15 10 mM Tris-HCL, pH 7.5, 5% glycerol, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 100 mM NaCl and 1yg poly(dI-dC)-poly(dI-dC). For competition experiments, 100 ng of double stranded oligonucleotide containing either a Spl consensus site (5'-ATT CGA TCG GGG CGG GGC GAG C; SEQ. ID. NO.:20), the oligonucleotide used for gel retardation (see above) or a non-specific oligonucleotide (5'-GAG ACC GGC TCG AAC GCA ATC ATG T; 20 SEQ. ID. NO.:21) were preincubated for 15 min at room temperature with the nuclear extracts before the addition of the labeled oligonucleotide. For supershift experiments, 2-3 ug of polyclonal antibody against SpI (Pep2, Santa Cruz) or Sp3 (D20, Santa Cruz) were preincubated with the nuclear extracts. Reactions were loaded on a 0.5x TBE /4% non denaturing polyacrylamide gel and run for 2-3 h at 10 V/cm. Gels were dried and 25 autoradiographed. Site directed mutagenesis. Site directed mutagenesis was performed according to the method from Deng and Nickoloff(W.P. Deng and J.A. Nickoloff, Analyt. Biochem.200:81-88 [1992]) using the Transformer site directed mutagenesis kit (Clontech). In brief, phosphorylated oligonucleotides containing the desired mutation were annealed on the single-stranded PGL3 41 WO 00/29602 PCT/US99/08277 Basic plasmid (containing the fragment -190 to +144) together with the oligonucleotide 5' AAT CGA TAA GAA TTC GTC GAC CGA (SEQ. ID. NO.:22) that changes the unique Bam HI site to an Eco RI site. The complementary strand was extended and completed from the annealed oligos using T4 Polymerase and T4 Ligase. Selection for the mutant plasmid was 5 performed by two rounds of digestion with Bam HI and subsequent transformations, first into the repair deficient strain BMH 71-18 mutS and finally into DH5a. The entire promoter fragment was sequenced to verify desired mutations and to exclude second site mutations. Because of the short distances between GC boxes 1+2 and 3+4, oligonucleotides were designed to mutate both GC boxes simultaneously. Mutations in all 4 GC boxes were 10 introduced by simultaneously adding oligos 1+2 and 3+4. All oligonucleotides used in these experiments were 5'-phosphorylated. The following oligonucleotides were used (mutated bases underlined): GC box 1: CCC CGC CCT GCC CCT TAC AGC CGG CCA CC (SEQ. ID. NO.:23), GC box 2: CCA ACC CTG CCC TTA CCT GCC CCG (SEQ. ID. NO.:24), 15 GC box 3: CCC TGC CCC TTC CGG CCC GGC C (SEQ. ID. NO.:25), GC box 4: CTG CCC TTC CCT TCC CTG CCC C (SEQ. ID. NO.:26), GC boxes 1+2: GCC CAA CCC TGC CCT TAC CTG CCC CTT ACA GCC GGC CAC CTC (SEQ. ID. NO.:27), GC boxes 3+4: CTT CCC TGC CCT TCC C TT ACC TGC CCC TTA CGG CCC GGC CCG 20 GCC (SEQ. ID. NO.:28). The potential CDE element in the cylin Al promoter was mutated using the following oligonucleotide: CCA CCT CTT AAC AAG CTT CCT CCA GTG CA (SEQ. ID. NO.:29). The cyclin Al-EGFP construct was finally constructed by cloning a Bgl1I - HindIII 25 fragment from the PGL3-Basic-Cyclin Al Promoter construct into the promoterless EGFP-1 (Clontech) plasmid. Example 13: Genomic cloning and gene structure of the human cyclin Al gene. A human genomic lambda phage library was screened using the cDNA of cyclin Al as a probe. Several clones containing pieces of the gene were obtained and one clone with a 42 WO 00/29602 PCT/US99/08277 14.5 kb insert contained the entire gene. A 2.2 kb fragment at the 5' end of the gene was subcloned and sequenced. The 2.2 kb fragment contained the first intron and parts of exon 2. The other exon-intron boundaries were analyzed by PCR-amplification and sequencing using sets of primers that span the entire coding region. The human cyclin Al gene consists of 9 5 exons and 8 introns which extend over ~-13 kb. Example 14: Analysis of transcription start sites. Transcription start sites were determined using primer extension analysis and 5' RACE. Primer extension was carried out as outlined in Example 12. A sample without RNA 10 and a sample of t-RNA (10 pg) were used as negative controls. The primer extension products shown in Fig. 2 are indicated by an asterisk above the appropriate nucleotide of the indicated sequence. Starting points of the RACE products are indicated by an arrow underneath the sequence. The number of RACE clones (total 25) starting at a particular base is indicated by the number shown below the arrows. The site where 44% (11/25) RACE 15 clones started was assigned +1. Both methods demonstrated the existence of several transcription start sites. The PCR product from the RACE reaction consisted of a single band of~450 bp. Sequencing of the inserts after cloning revealed that 80% of the RACE products (20/25) started from a 4 base pair stretch, and thus the predominant start site was assigned +1. This site is 130 bp upstream 20 of the translation initiating ATG codon. Primer extension analysis identified the same start sites, but minor products were also seen further upstream (Fig. 2). The major start site coincides with the RACE results of the 5' end of the cDNA clone described by Yang et al. (1997). Neither RACE clones nor primer extension assays showed evidence for a second transcript in myeloid leukemia cells that could indicate a transcriptional start site upstream of 25 the second ATG in intron 1 (data not shown). Example 15: Potential transcription factor binding sites in the 5' upstream region. Genomic sequences 1299 bp upstream of the transcription start site were cloned and sequenced. No TATA box was found in proximity to the putative transcriptional start site. The main transcriptional start site is likely to function as an initiator region (Inr) since the 43 WO 00/29602 PCT/US99/08277 sequence "CCAGTT" is very similar to the consensus Inr sequence "TCA G/T T T/C" (T.W. Burke and J.T. Kadonaga, Genes & Development 1:3020-31 [1997]). No DPE element was found downstream of the main transcriptional start site. (See id.). Several potential binding sites for transcription factors occur within the sequence. 5 Figure 3 represents the 5' upstream region of the human cyclin Al gene. The first bases of the different fragments are indicated, as well as potential transcription factor binding sites between -190 to +144. The transcriptional start site is marked with an arrow and the translational initiation codon is boldfaced. An E2F site is located at nt. +139 to +144 and another possible site starting at +67. A site that resembles the cycle dependent element 10 (CDE) of the cyclin A2 promoter was found at -28. (J. Zwicker et al., EMBO J. 14:4514-22 [1995]). However, this element was located on the antisense strand. No cell cycle genes homology region (CHR) was found. Potential Myb sites were predicted starting at positions +2, -27 and -66. However, c-myb protein bound only at the first two of these sites. (See Fig. 3 and Example 23). The nucleotide sequences contain two CpG islands of up to 90% GC 15 content reaching from -1000 to -700 and from -550 to -50. Multiple GC boxes are found in this region, and six GC boxes grouped as three double sites are located between nt -150 and -45. Example 16: Functional analysis of the basal activity of the cyclin Al promoter. 20 Portions of the cyclin Al promoter were Pfu-PCR amplified and cloned into the promoterless PGL3-Basic Luciferase vector. Promoter activity was analyzed after transient transfection into Hela cells. Figure 4 represents transactivation activity of cyclin Al promoter fragments in Hela cells. Activity of 5' deletion constructs was analyzed in luciferase assays. Values are expressed as fold activation (PGL3-Basic=1); means and SEM of three 25 independent experiments are shown. The construct containing nucleotides from -1299 to +144 from the 5' cyclin Al upstream region showed significant promoter activity when cloned in the sense direction. The same fragment cloned in the opposite direction or a construct containing solely exon 1 and intron 1 did not show promoter activity (data not shown). Deletions from the 5' end were made for the -1299 to +144 fragment using exonuclease 30 III treatment. Transient transfection and subsequent luciferase assays revealed the strongest activity occurred in the construct containing the fragment from -190 to +144 bp. (Fig. 4). 44 WO 00/29602 PCT/US99/08277 Both the -1299 to +144 and the -190 to +144 constructs exhibited promoter activity in a variety of cell lines including Cos-7(monkey kidney cell), MCF-7 (breast cancer cell), U937 (myeloid leukemia cell), KCL22 (myeloid leukemia cell), PC3 (prostatic cancer cell), Hela (cervical cancer cell) and Jurkat (T-cell lymphoma). (Data not shown). In all of these 5 mammalian cell lines, luciferase activities generated by the -190 to + 144 construct were higher than those by the -1299 to +144 construct. Constructs with a 5' end containing less than 190 bp upstream of the transcription start site showed a progressive loss of promoter activity. A construct containing bp -37 to +144 showed only two-fold higher activity than the promoterless vector PGL3-Basic. 10 Example 17: Role of Sp I and GC boxes for transcriptional activity of the cyclin A l promoter. TATA-less promoters frequently depend on GC boxes to activate transcription. (J. Lu et al., J. Biol. Chem. 269:5391-5402 [1994]; M.C. Blake et al., Molec. Cell. Biol. 10:6632-41 [1990]). One of the main classes of transcription factors binding to these sites are Sp 1 family proteins (A.J. Courey and R. Tjian, Cell 55:887-98 [1988]; A.P. Kumar and A.P. Butler, 15 Nucleic Acids Res. 25:2012-19 [1997]; G. Hagen et al., J. Biol. Chem. 270:24989-94 [1995]). The cyclin Al promoter contains at least six potential GC boxes between 190 and 37 bp upstream of the transcription start site. The importance of Spl for the activity of the cyclin Al promoter, was demonstrated by the use of various promoter constructs that were transfected into the Drosophila cell line S2, which lacks endogenous Spl and Sp3. 20 Figure 5 shows activity of the cyclin Al promoter fragments in the Drosophila cell line S2. Activity is indicated as fold activation of PGL3-Basic as compared to reporter gene activity without addition of SpI expression plasmid. The punctated and solid bars represent activities without and with Spl co-expression, respectively. When transfected alone, the activity of all cyclin Al promoter fragments was not significantly different from the empty 25 vector control. (Fig. 5, dotted bars). The addition of a SpI expression plasmid strongly activated transcription by 15- to 25 fold from the cyclin Al promoter. (Fig. 5, solid bars). Increased transcriptional activity was observed only for constructs containing sequences starting between -1299 and -112 bp upstream of the transcription start site. The construct containing the nucleotide sequences 30 between -37 and +144 did not show any increase in activity, implying that SpI binding sites 45 WO 00/29602 PCT/US99/08277 between -112 and -37 are essential for SpI mediated transcriptional activity of the cyclin Al promoter in Drosophila cells. This region contains four GC boxes which are grouped in two pairs. (Fig. 3). The ability of Sp 1 and other Sp 1 family members to bind to these sites was shown by 5 gel-shift experiments performed using 5 ig Hela nuclear extract. Complexes bound to a 3p end labeled oligonucleotide containing GC box Nos. 1 and 2, and the labeled oligonucleotide containing GC boxes Nos. 3+4. Binding was competed away with a 100-fold excess of cold SpI consensus oligonucleotide and by a 100-fold excess of cold oligonucleotides using either GC box Nos. 1 + 2 or GC box Nos. 3+4. A 100-fold excess of a non-specific oligonucleotide 10 did not alter specific complex binding. Antibodies against Spl were added to some samples, and antibodies against Sp3 were present in reactions in others. These supershift experiments with antibody against either Sp 1 or Sp3 demonstrated the presence of Sp 1 in one complex, and the presence of Sp3 in two other complexes. (Data not shown). The relevance of the GC boxes for promoter activity was further studied by mutational 15 analysis. Point mutations were made in each GC box. Each mutant was tested either alone with the remaining sites unaltered or in combination with the other mutant sites. Luciferase analyses demonstrated that a mutation in either GC box No. 1 or 2 reduced promoter activity by about 40 and 75%, respectively, whereas a single mutation of either GC box No. 3 or 4 did not have a major effect on promoter activity. 20 Figure 6 shows effects of GC box mutations on promoter activity. Individual GC boxes or their combinations were mutated and transiently transfected into Hela cells. Activity of the wild type construct containing nt -190 to +144 was set as 100%. Wild type GC boxes are indicated in white and mutated GC boxes are shown in black. Mutation of GC Box Nos. 1 and 2 together, decreased promoter activity by 85%. The presence of at least one of the two 25 upstream GC boxes (GC Box Nos. 3 or 4) being intact was essential for cyclin Al promoter activity, as mutations in both reduced promoter activity by about 80%. Mutations of all four GC boxes reduced activity of the cyclin Al promoter by 95%. Example 18: Cell cycle regulation of promoter activity. The concentration of cyclins vary during the cell cycle, and one mechanism of their 30 regulation occurs at the transcriptional level. (R. Muller, Trends in Genetics 11:173-78 46 WO 00/29602 PCTIUS99/08277 [1995]). To analyze cell cycle regulation of promoter activity, transiently transfected cells were arrested in different phases of the cell cycle and subsequently analyzed for luciferase activity. Cell cycle regulated activity was found for the full length promoter as well as for the construct containing the -190 to +144 fragment. 5 Figure 7 shows Cell cycle regulated activity of the cyclin Al promoter in Hela cells. In Figure 7(A), Hela cells were cell cycle arrested after transfection with a luciferase construct containing nt -190 to +144 of the cyclin Al promoter. Cells were subsequently analyzed for luciferase activity. Cell cycle synchronization was confirmed by flow cytometry (data not shown). The bars represent means and SEM of at least three independent experiments. 10 Promoter activity at 0 h was set as 1. The cyclin Al promoter activity was relatively low during the G/G, phase. It increased after the cell cycle progressed beyond the G,/S boundary. In Figure 7(B), Hela cells were synchronized at the GI/S boundary using aphidicolin, following transient transfection and serum starvation. Cells were released from the block and harvested at the indicated time points for luciferase and cell cycle analyses. The graph depicts 15 data from a representative experiment. When transiently transfected Hela cells were released from an aphidicolin block, luciferase values started to increase after 6 hours and reached a maximum after 12-16 h. Figure 7(C) shows cell cycle distribution at the different time points of the time-release experiment. The hatched, open and solid bars represent G 1 , S and G 2 /M phases, respectively. 20 The highest levels of activity were observed in the S and G 2 /M phases. The maximum promoter activity corresponded to the percentage of cells present in the S and G 2 /M phases. This is consistent with data showing that levels of cyclin Al mRNA accumulate during S phase, with the highest levels present at the S and G 2 /M phases. (Yang et al., Mol. Cell. Biol. [in press 1999]). 25 Fragments containing nucleotides -1299 to +144, -190 to +144, or -190 to +13 performed similarly in all these experiments (data not shown). Various point mutations and deletions were generated in the presumed E2F sites and the suspected CDE element in order to define the regions that are relevant for cell cycle regulation of the cyclin Al promoter. Activity of the wild type construct (containing the -1299 30 to +144 fragment) in aphidicolin arrested cells was set as 1.0 and compared to the other constructs. Only a 40% decrease was detected for the construct containing the four mutated 47 WO 00/29602 PCT/US99/08277 GC boxes. Nucleotides in the suspected CDE in antisense direction were mutated in the construct called mutation -19 to -24. There was a strong increase in promoter activity after release from a G,/S block by aphidicolin. Constructs lacking the four GC boxes either due to mutation or 5' deletion were not induced upon entering the S phase. No significant difference 5 was observed between wild type and the mutation -19 to -24 construct. These findings are consistent with repression of SpI mediated activity in the G1 phase of the cell cycle. Selective repression of SpI mediated activity by Sp3 has been demonstrated to be relevant in cell cycle regulated promoters containing several Spl sites. The dihydrofolate reductase (DHFR) promoter contains four Spl sites and is specifically repressed by Sp3. (M.J. 10 Birnbaum et al., Biochemistry 34:16503-08 [1995]). Besides repression by Sp3, other mechanisms probably contribute to repression of the cyclin Al promoter in Gl. Studies have shown that repression of glutamine rich activators such as SpI and NF-Y is the predominant mechanism of cell cycle regulation for several promoters (J. Zwicker et al., (1995) Nucleic Acids Research 23:3822-30 [1995]; J. Zwicker et al., (1998) Nucleic Acids Research 26:4926 15 4932 [1998]). However, none of the known repressor elements (CDE, CHR, E2F) appears to be relevant for the cyclin Al promoter. A 3' deletion construct (-190 to + 13) was generated by PCR that deleted the two presumed E2F sites downstream of the transcriptional start site. Mutations in these two presumed E2F sites, the mutation in the inverted presumed CDE element, and the 3' deletion 20 showed an indistinguishable pattern of cell cycle regulation when compared to the wildtype. (Data not shown). Hence, these E2F sites and the inverted CDE element are unlikely to play a role in cell cycle regulation of the promoter. Analysis of 5' deletions and the constructs containing the mutated GC boxes revealed that the four GC boxes are essential for cell cycle regulation. The 25 activity of the construct containing the mutated GC boxes showed 60% of the activity of the wild type reporter construct in G, phase. However, the activity of the construct failed to increase when cells entered S phase and showed only 4% of the wild type cyclin Al promoter activity. Similar data were obtained for the 5' deletion lacking the four GC boxes. Example 19: Screening transgenic vertebrates for the presence of cyclin Al-EGFP DNA 30 Transgenic mice were screened by PCR-amplification of DNA sampled from their 48 WO 00/29602 PCTIUS99/08277 tails. The mice were anesthetized with metafane, and a 1-cm piece of tail tip was cut using a sterile scalpel. The tail biopsy was incubated with 1 00pg of Proteinase K in 700/IL lysis buffer (10 mM Tris, pH7.5, 1mM EDTA, and 10% SDS) overnight at 50'C. The lysate was extracted once with 500 1 A phenol, twice with phenol/chloroform (1:1) and was precipitated 5 with ice cold isopropanol. The precipitate was centriftiged and the pellet was washed once with 70% ethanol. The pellet was allowed to air dry for 30 minutes at room temperature and was then resuspended in 200pL 10 mM Tris, pH 7.5, 0.1 mM EDTA. The tail DNA was allowed to incubate at 650 C for 10 min, and it was then stored at 40 C. For each sample, 100 ng of tail DNA was added to a PCR cocktail mix in a total 10 volume of 50pL. For each sample tube, the PCR cocktail contained 10pL of Qiagen Q buffer, 5puL of PCR buffer (Qiagen), dNTPs and a pair of EGFP-specific primers, 5'-TTG TCG GGC AGC AGC ACG GGG CCG-3' (SEQ. ID. NO.:30) and 5'-TCA CCG GGG TGG TGC CAT CCT TGG-3' (SEQ. ID. NO.:3 1). A 600 bp fragment was amplified. A positive control contained the cyclin Al-EGFP plasmid DNA, and a negative control contained no DNA. 15 Example 20: Selectable fluorescent vertebrate germ cells expressing EGFP by the cyclin Al promoter Five lines of transgenic mice were generated that contain DNA construct pCyclinAl EGFP-1 and express the flourescent green reporter gene (EGFP) under the control of the cylin Al promoter (cyclin Al-EGFP mice). Flourescent green protein is seen in male germ cells 20 with FITC filter. The mice were transfected with a construct containing a 1.4 kb 5' flanking region DNA of human cyclin Al including, nt. -1299 to + 144, inserted into the BgII/HindII site of the promoterless fluorescent green protein (EGFP) expression vector pEGFP-1 (Clontech; Figure 1). The vector also contained a SV40 splice and polyadenylation signal 3' to the EGFP gene, as well as kanamycin and neomycin resistance genes for selection purposes. 25 The pCyclinAl-EGFP-1 construct was expressed in Cos-7, MCF-7, and U937 cells in vitro. For the generation of transgenic mice, the vector sequences were removed from the construct, and the DNA fragment which comprised the cyclin Al promoter, the EGFP gene, and the SV40 splice and polyadenylation signal was purified on a 10%-40% sucrose gradient. One milliliter fractions were collected from the gradient, and the fraction containing the construct 49 WO 00/29602 PCT/US99/08277 was dialized in a slide cassette dialysis membrane (Pierce) against 4 liters of 10 mM Tris, pH 7.5, 0.1 mM EDTA for 48 hours with 3 changes. The purified pCyclinAl-EGFP construct was used to generate transgenic mice by microinjection of DNA into the pronucleus of fertilized eggs. (Gordon and Ruddle, 1980; 5 Hogan, Costantini and Lacy, 1996). The surrogate mothers delivered 38 pups, 8 (21%) of which had integrated the transgene as was shown by PCR and Southern Blot analysis. Two of the founder animals failed to breed and one did not show expression of the transgene in the testis. The remaining 5 animals expressed EGFP in male germ cells. Example 21: FACS Analysis of Testicular Cells from Transgenic Mice 10 Testicular cell suspensions from cyclin Al -EGFP transgenic mice were made using an enzymatic digestion method modified from Dym et al. (M. Dym et al., Biol. Reprod. 52:8 9 [1995]). Testes were dissected from euthanized transgenic mice and decapsulated. The seminiferous tubules were spread apart in Enzyme Mix I: Collagenase I (1 mg/mL; bovine pancreatic, Sigma) in modified HTF medium (Irvine Scientific) containing 1% BSA (1 15 mg/mL; Sigma, embryo tested) and incubated for 10 min at 37'C. This first enzymatic step is aimed at eliminating cells external to the seminiferous tubules, such as Leydig cells. The tubules were then lifted into 1 mL of Enzyme Mix II: Collagenase 1 (1 mg/mL; bovine pancreatic), trypsin type III (50 mg/mL; Sigma), DNAase I (1 mg/mL; Sigma) in modified HTF medium, which contained BSA (1 mg/mL), and the tubules were cut into small 20 pieces using sterile needles attached to 1 mL syringes. The cut tubules were incubated in Enzyme Mix II for 15 min at 37'C. After this incubation, the cells were washed 3 times in 10 mL of the modified HTF by centrifugation at 2,000 rpm and were resuspended. The cells were resuspended in 2 mL of modified HTF and were filtered through 70 yim mesh (Corning) to be analyzed by FACS. Typically, about 3 x 107 testicular cells were harvested from a 25 mature male mouse. The cells were tested for viability with trypan blue. Kidney cells were prepared in the same way except that the first collagenase incubation was omitted. The transgenic testicular cells were analyzed for fluorescence and for sideward scatter using a Becton-Dickenson cell sorter on channel 1 (FITC for Green Fluorescent Protein). Based on these properties, four populations were distinguishable: 1) a EGFP-negative 50 WO 00/29602 PCT/US99/08277 population; and populations 2 through 4, which had increasing fluorescence and scatter properties reflecting different cell types. The cyclin Al -EGFP cells were also tested with PE conjugated PE anti-c-kit antibodies and analyzed with FACS. The FACS analysis showed that there is a population of fluorescent 5 cells which expresses EGFP under the cyclin Al promoter and that these cells are positive for c-kit. Some of the c-kit cells were not EGFP positive. Figure 8 shows frozen sections from testis of adult mice that were cut, rinsed in phosphate buffered saline (PBS) for 10 min and analyzed by confocal laser scanning microscopy. Whereas no fluorescence could be observed in testicular tubuli of control mice 10 (Fig. 8a), strong and highly specific expression of EGFP (Fig. 8b and c) was detected in testis of transgenic mice. Maximal EGFP expression was observed during and after the first meiotic division and a weaker staining was present in spermatogonia. Magnifications are 400x (Fig. 8a and b) and 100x (Fig. 8c). Example 22: The effect of CpG methylation of the cyclin Al promoter. 15 Bisulfite sequencing was carried out according to the method described by Clark et al. with minor modifications. (S.J. Clark et al., High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997 [1994]). Ten mg of DNA was incubated with the bisulfite/hydroquinone solution for six hours. A nested PCR was performed (detailed Primer information will be provided on request) and the final PCR product (ca. 400 bp) was gel 20 purified. The PCR products were either blunt end cloned and at least 10 clones were sequenced, or the purified PCR product was directly sequenced using "P-cycle sequencing of nucleotides. In vitro methylation and luciferase assay. The cyclin Al promoter - luciferase reporter construct was in vitro methylated by SssI following the recommendations of the manufacturer 25 (New England Biolabs). (S. Kudo, Methyl-CpG binding protein MeCP2 represses Spl-activated transcription of the human leukosialin gene when the promoter is methylated, Mol. Cell. Biol.18:5492-99 [1998]). S2 Drosophila cells were transfected as described previously using 1 pg of methylated or mock-methylated luciferase - reporter plasmid, 100 ng of Spl expression plasmid and 1 ptg of a CMV-P-galactosidase expression plasmid used for standardization 30 purposes. One pg of human MeCP2 expression vector or empty vector control were co 51 WO 00/29602 PCT/US99/08277 transfected. (S. Kudo [1998]). Luciferase experiments were performed in duplicate and independently repeated three times. The human MeCP2 expression vector was a kind gift from Dr. S. Kudo, Hokkaido Institute, Sapporo, Japan. As described above, the cyclin Al promoter is highly GC rich and bears a CpG 5 island that extends over several hundred base pairs and ends 50 base pairs upstream of the main transcriptional start site. When the methylation pattern of the CpG dinucleotides in the critical parts of the promoter was analyzed using bisulfite sequencing (S.J. Clark et al. [1994]), a high degree of CpG methylation was observed in somatic, adherent cell lines but not in cyclin Al expressing leukemia cell lines. Hypomethylation in the leukemic cell 10 lines was clearly restricted to the CpG island since a CpG at nt. +114 outside of the CpG island was found to be completely methylated in all cell lines tested. To analyze whether methylation of the cyclin Al promoter was associated with gene silencing, MG63 osteosarcoma cells were stably transfected with a Cyclin Al promoter - EGFP construct. After prolonged culture of cells (2 months), there were two populations of neomycin 15 resistant cells, i.e., that showed stable integration of the transgene. One part of the population maintained relatively high expression of EGFP (Fig. 9a, left hand peak), while a fraction of the population of neomycin-resistant cells lost EGFP expression over time. (Fig. 9a, right hand peak). Both EGFP-expressing and non-expressing cell populations were sorted by flow cytometry and analyzed for CpG methylation of the cyclin Al promoter transgene. Specific primers were 20 designed for the promoter-EGFP construct to avoid analysis of the endogenous cyclin Al locus. The transgenic cyclin Al promoter was substantially non-methylated in the expressing cells (Fig. 9a, left hand sequencing ladder), but cells that had lost EGFP expression showed strong methylation of the cyclin Al promoter. (Fig. 9a, right hand sequencing ladder). Studies recently have shown that the methyl CpG binding protein 2 (MeCP2) is an 25 important mediator of methylation-induced gene silencing. (P.L. Jones et al., Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription, Nature Genetics 19: 187-91 [1998]); X. Nan et al., Transcriptional repression by the methyl CpG-binding protein MeCP2 involves a histone deacetylase complex, Nature 393:386-89 [1998]; X. Nan et al., MeCP2 is a transcriptional repressor with abundant binding sites in genomic 30 chromatin, Cell 88:471-78 [1997]). MeCP2 binds specifically to methylated DNA and recruits co-repressors, such as mSin3A, leading to the deacetylation of histones and 52 WO 00/29602 PCT/US99/08277 repression of transcriptional activity. (X. Nan et al. [1997] and [1998]). The human leukosialin gene is one of the genes shown to be negatively regulated by MeCP2 when its promoter is methylated. (S. Kudo [1998]). Leukosialin (similar to cyclin Al) is tissue specifically expressed in hematopoietic cells and its transcriptional activity depends on the 5 SpI transcription factor. Using S2 Drosophila cells that do not express endogenous MeCP2, it was analyzed whether co-transfected MeCP2 would suppress activity of the methylated (+) or unmethylated (-) cyclin Al promoter (Fig. 9b). Upon transfection of in vitro methylated cyclin Al promoter constructs into Drosophila cells, we noticed 3-fold repression without MeCP2. When MeCP2 was co-expressed with the methylated cyclin 10 Al promoter constructs, promoter activity was inhibited by 12-fold, indicating that MeCP2 can suppress transcriptional activation of the methylated cyclin Al promoter. (Fig. 9b). Since methylation appeared to be involved in regulation of the cyclin Al gene in the mammalian cell lines, it was investigated whether the site of chromosomal integration would determine the patterns of methylation and expression of the transgenic cyclin Al promoter. Four 15 lines of transgenic mice carried the cyclin Al promoter - EGFP reporter construct, as described above; this was the same nucleic acid construct used to generate the stable MG63 cell line. All lines of transgenic mice showed highly specific expression in the testis resembling the expression pattern previously determined by in-situ hybridization techniques. (Fig. 8; C. Sweeney et al. [1996]). The EGFP expression pattern in testis was indistinguishable among the different lines. 20 The cyclin Al promoter was able to direct tissue specific expression in the testis independent of the chromosomal integration site. The methylation status of a transgene is thought to be largely determined by either the chromatin structure at the site of integration, the cis-acting sequences in the transgene, and/or the influence of a locus control region. (J.R. Chaillet et al., Parental-specific methylation ofimprinted transgene is established during gametogenesis and progressively changes 25 during embryogenesis, Cell 66:77-83 [1991]; K. Matsuo et al., An embryonic demethylation mechanism involving binding oftranscription factors to replicating DNA, EMBO J. 17:1446-53 [1998]; M. Brandeis et al., Nature 371:435-38 [1994]). Transgene activity has also been reported to be associated with hypomethylation. (E.g., Pikaart et al. [1998]). Analysis of the methylation status of the human cyclin Al promoter in the testis of four transgenic mouse lines showed that 30 the promoter and the transgene were not methylated in the testis of two lines. However, the promoter and the transgene were heavily methylated in testis of the two other lines. No difference 53 WO 00/29602 PCT/US99/08277 in the EGFP expression pattern in testis could be found between the murine lines either with or without CpG methylation. To confirm that EGFP was highly expressed despite methylation in these male germ cells, testis cells were disaggregated and sorted by flow cytometry as described above. 5 Bisulfite sequencing confirmed that methylation of the cyclin Al promoter in germ cells did not inhibit expression of the transgene in testis. One of the murine lines without methylation in testis showed promoter methylation in the kidney and bone marrow, but not in the liver and did not express the transgene in any organ besides the testis. The silencing of a gene in the absence of methylation has been described for other genes as well. (E.g., 10 P.M. Warnecke and S.J. Clark, DNA methylation profile of the mouse skeletal alpha-actin promoter during development and differentiation, Mol. Cell Biol. 19:164-72 [1999]). One transgenic murine line did not show a significant degree of methylation of the transgenic cyclin Al promoter anywhere and expressed EGFP in a subset of cells in the kidney (25%), spleen (10%) and bone marrow (16%). Taken together, transcriptional activity of 15 the cyclin Al promoter transgene outside of the testis was only seen when the promoter was not methylated. This finding might supports a linkage of methylation of the cyclin Al promoter to transcriptional repression in somatic cells. In contrast, methylation of the cyclin Al promoter - EGFP transgene did not lead to silencing in murine male germ cells. Example 23: Transactivation of cyclin Al promoter by c-myb. 20 Analysis of the cyclin Al promoter sequence showed potential binding sites for c myb within the -190 to +144 fragment. (Fig. 3). To analyze further the differences in expression, four human cell lines were chosen that differed in the degree of cyclin Al expression. Two were derived from myeloid cells (U937, KCL22) and two others from solid carcinomas (PC3 prostate cancer, Hela cervical carcinoma). Expression of cyclin Al 25 was analyzed by RT-PCR followed by Southern blotting. The RT-PCR results confirmed that cyclin Al expression differed between the myeloid and the non-myeloid cell lines. The highest RNA levels were found in U937 and the lowest occurred in Hela cells. To analyze whether differences in RNA levels could be related to promoter activity, the cyclin Al promoter was transiently transfected into several myeloid and 30 adherent cells lines (Fig. 10). Both cyclin Al promoter luciferase constructs ranging from 54 WO 00/29602 PCT/US99/08277 -1299 to +144 and from -190 to +144 showed activity in all four cell lines (Fig. 10). The reporter activity of the shorter promoter fragment was always higher than the activity of the longer fragment. In addition, the activity of the cyclin Al promoter was higher than that of the SV40 promoter (without enhancer) in all four cell lines. 5 The cyclin A2 promoter is tightly cell cycle regulated and is assumed to be transactivated in all cycling mammalian cells. Activity of the cyclin A2 promoter was detectable in all four cell lines, but the degree of activity was inversely correlated with the cyclin Al promoter activity. Cyclin A2 promoter activity was higher in PC3 and Hela cells and it was lower in the myeloid cell lines as compared to the cyclin Al promoter activity. 10 (Fig. 10). Preferential activity of the cyclin Al promoter in myeloid cells (compared to the cyclin A2 promoter) was evident for both promoter constructs tested. The inverse relationship between cyclin A2 and cyclin Al was also present at the RNA level in samples from patients with acute myeloid leukemia. (R. Yang et al. [1999]). However, activity of the cyclin Al promoter by transient transfection was not limited to the myeloid 15 cell lines but was also present in PC3 and Hela cells. The tissues from which these cell lines derived express very low levels of cyclin Al. An explanation could be that transcription factors expressed in the cell lines, but not expressed in the normal tissue, lead to aberrant promoter activity. One transcription factor expressed in a wide variety of cell lines is c-myb. Western blot analysis demonstrated expression of c-myb in all four cell 20 lines as well as in ML- 1, another myeloid cell line that expresses high levels of cyclin Al. The non-myeloid cell lines appeared to have only a high molecular weight form while the myeloid lines had both a high and a low molecular weight form. This may reflect a phosphorylated and a non-phosphorylated myb protein. 55 WO 00/29602 PCT/US99/08277 To analyze promoter transactivation by c-myb, a c-myb expression vector was transfected (0 to 5 pg of co-transfected plasmid DNA encoding c-myb) along with the -190 to +144 cyclin Al promoter construct into CV-1 cells that do not express c-myb. A dose dependent increase in cyclin Al promoter activity occurred (Fig. 11 a), and no increase in 5 activity was observed when c-myb was co-transfected with the empty reporter plasmid (data not shown). The same experiments were repeated using U937 myeloid cells, which express rather low levels of c-myb. As in CV-1 cells, in U937 c-myb clearly transactivated the promoter with maximal activity occurring when 3 pig of c-myb-encoding DNAs were co transfected. (Fig. 1 Ib). These findings indicate that the cyclin Al promoter can be 10 transactivated by c-myb in adherent as well as in myeloid cell lines. To analyze whether c-myb directly affected the cyclin Al promoter, binding of c-myb protein to the predicted myb binding sites in the promoter region was examined. Gel-shift experiments were performed with c-myb protein expressed in Cos- 1 cells and 3 P-labelled oligonucleotides constituting the myb-binding sites of the cyclin Al promoter. Experiments 15 showed that c-myb was able to bind to the cyclin Al promoter at the +2 to +5 binding site. Weak binding was seen at the potential myb site at -27 to -24 and no specific binding at the site at position -66 could be detected. Nuclear extracts from Cos- 1 cells expressing c-myb led to the appearance of two new bands compared to nuclear extract prepared from Cos-1 cells transfected with empty expression vector, only. Specificity of the binding to the +2 site 20 was confirmed using competitor oligonucleotides and c-myb specific antibody. Addition of c-myb specific antibody led to extinction of both bands. The faster migrating band appeared at the same position as the c-myb band produced on a myb consensus binding site (data not shown). Therefore the slower migrating band might be a complex of proteins with one of them being c-myb. No c-myb binding could be detected using a potential binding site at -66. The 25 binding site at -27 showed a rather weak band after incubation with the c-myb expressing nuclear extract. (Data not shown). Also, the band did not disappear after addition of c-myb 56 WO 00/29602 PCTIUS99/08277 antibody implying that c-myb either did not or only weakly bound this site. To test whether c-myb activation of the promoter was affected by alteration of the myb binding sites, different sites were mutated and the resulting constructs were transfected in KCL22 cells. These cells showed the highest c-myb expression of all the cell lines. Abrogation of the myb 5 site at +2 clearly diminished promoter activity by 50% whereas a mutation at either -27 or mutation of the ets site at -15 did not lead to a decrease in promoter activity. The myb site at +2 to +5 is close to the transcriptional start site and the base pairs surrounding the transcriptional start site could function as an Initiator (Inr). To rule out that the observed effects of the mutation at +2 depended on the loss of binding of the basal transcriptional 10 machinery, we transfected the mutated reporter construct together with the c-myb expression plasmid or an empty vector control into CV-1 cells and compared the results with transfections using the wildtype promoter plasmid. The mutation at +2 led to a minor reduction in promoter activity when transfected with the empty vector control. However, transactivation of the mutated reporter plasmid by c-myb was reduced by more than 50%, 15 indicating that c-myb can transactivate the cyclin Al promoter through this site. Other sites or indirect effects may contribute to the cyclin Al promoter activation, because the mutation at +2 did not abolish the increase in promoter activity entirely. Different amounts of c-myb were co-expressed with a cyclin Al promoter construct (-190 to +144 fragment). Empty vector was used to reach the same total amount of DNA in all experiments. Mean and 20 standard error for three independent experiments are shown. The foregoing examples being illustrative but not an exhaustive description of the embodiments of the present invention, the following claims are presented. 57
Claims (132)
1. A method of obtaining a selectable transgenic stem cell of a vertebrate, comprising: administering to a gonad of a male vertebrate a transfection mixture comprising at least one transfecting agent and at least one polynucleotide comprising a transcriptional unit of a stem cell-specific promoter operatively linked to a DNA encoding a fluorescent or light-emitting protein, under conditions effective to reach a germ cell or germ cell precursor of the male vertebrate; and causing said polynucleotide to be taken up by, and released into, said germ cell or precursor cell; incorporating said polynucleotide into the genome of said germ cell or precursor cell, whereby a selectable transgenic stem cell is obtained expressing said fluorescent or light emitting protein, by which said stem cell can be isolated or selected from a non-stem cell.
2. The method of Claim 1, further comprising, after incorporating said polynucleotide into the genome of said germ cell or precursor cell, breeding said male vertebrate with a female of its species to obtain a transgenic progeny expressing said fluorescent or light emitting protein in at least one of its stem cells.
3. The method of Claim 2, wherein breeding is by in vitro or in vivo fertilization of an ovum of said female.
4. The method of Claim 1, wherein said stem cell-specific promoter is a human cyclin Al promoter having a nucleotide sequence (SEQ. ID. NO.:2), or an operative fragment or non human homologue thereof, or an operative derivative of any of these.
5. The method of Claim 1, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit, whereby methylation in vivo of said promoter sequence is substantially prevented.
6. The method of Claim 5, wherein at least one of said insulator element(s) is a chicken p-globin insulator element. 58 WO 00/29602 PCT/US99/08277
7. The method of Claim 1, wherein said fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaequorin.
8. The method of Claim 1, wherein said vertebrate is a mammal or bird.
9. The method of Claim 1, wherein said vertebrate is a human, non-human primate, mouse, rat, rabbit, gerbil, hamster, canine, feline, ovine, bovine, swine, pachyderm, equine, or a farm or marine mammal.
10. The method of Claim 1, wherein said vertebrate is a duck, chicken, goose, ostrich, emu, dove, quail, guinea fowl, or turkey.
11. The method of Claim 1, wherein said germ cell or precursor cell develops into a maturing male gamete after said polynucleotide is incorporated into the genome of said germ cell or precursor cell.
12. The method of Claim 2, wherein a stem cell of said progeny is grown in vitro.
13. The method of Claim 12, wherein said stem cell is grown in the presence of an inhibitor of DNA methylation.
14. A selectable transgenic stem cell obtained by the method of Claim 1.
15. The selectable transgenic stem cell of Claim 14, wherein said stem cell is a pluripotent, multipotent, bipotent, or monopotent stem cell.
16. The selectable transgenic stem cell of Claim 14, wherein said stem cell is a spermatogonial, embryonic, osteogenic, hematopoietic, granulopoietic, sympathoadrenal, mesenchymal, epidermal, neuronal, neural crest, 0-2A progenitor, brain, kidney, pancreatic, liver or cardiac stem cell.
17. The selectable transgenic stem cell of Claim 14, wherein said stem cell is a selectable transgenic male germ cell. 59 WO 00/29602 PCT/US99/08277
18. A transgenic non-human vertebrate comprising the stem cell of Claim 14.
19. The transgenic non-human vertebrate of Claim 18, wherein said vertebrate is a non human mammal or a bird.
20. Vertebrate semen comprising a maturing male gamete obtained by the method of Claim 11.
21. A method of producing a non-human transgenic vertebrate animal line having native germ cells, comprising: breeding the transgenic non-human vertebrate of Claim 18 with a member of the opposite sex of the same species; and selecting progeny for stem cell-specific expression of a xenogeneic fluorescent or light-emitting protein.
22. A method of obtaining a selectable transgenic stem cell of a vertebrate, comprising: administering to a gonad of a male vertebrate a transfection mixture comprising at least one transfecting agent and at least one polynucleotide comprising a transcriptional unit of a cyclin Al promoter sequence operatively linked to a DNA encoding a fluorescent or light-emitting protein, under conditions effective to reach a germ cell or germ cell precursor of the male vertebrate; and causing said polynucleotide to be taken up by, and released into, said germ cell or precursor cell; incorporating said polynucleotide into the genome of said germ cell or precursor cell, whereby a selectable transgenic stem cell is obtained expressing said fluorescent or light emitting protein, by which said stem cell can be isolated or selected from a non-stem cell.
23. The method of Claim 22, further comprising, after incorporating said polynucleotide into the genome of said germ cell or precursor cell, breeding said male vertebrate with a female of its species to obtain a transgenic progeny expressing said fluorescent or light emitting protein in at least one of its stem cells. 60 WO 00/29602 PCT/US99/08277
24. The method of Claim 23, wherein breeding is by in vitro or in vivo fertilization of an ovum of said female.
25. The method of Claim 22, wherein said cyclin Al promoter sequence comprises SEQ. ID. NO.:2, or an operative fragment or non-human homologue thereof, or an operative derivative of any of these.
26. The method of Claim 22, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit, whereby methylation in vivo of said promoter sequence is substantially prevented.
27. The method of Claim 26, wherein at least one of said insulator element(s) is a chicken p-globin insulator element.
28. The method of Claim 22, wherein said fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase or apoaequorin.
29. The method of Claim 22, wherein said vertebrate is a mammal or bird.
30. The method of Claim 22, wherein said vertebrate is a human, non-human primate, mouse, rat, rabbit, gerbil, hamster, canine, feline, ovine, bovine, swine, pachyderm, equine, or a farm or marine mammal.
31. The method of Claim 22, wherein said vertebrate is a duck, chicken, goose, ostrich, emu, dove, quail, guinea fowl, or turkey.
32. The method of Claim 22, wherein said germ cell or precursor cell develops into a maturing male gamete after said polynucleotide is incorporated into the genome of said germ cell or precursor cell.
33. The method of Claim 23, wherein a stem cell of said progeny is grown in vitro. 61 WO 00/29602 PCT/US99/08277
34. The method of Claim 33, wherein said stem cell is grown in the presence of an inhibitor of DNA methylation.
35. A selectable transgenic stem cell obtained by the method of Claim 22.
36. The selectable transgenic stem cell of Claim 35, wherein said stem cell is a pluripotent, multipotent, bipotent, or monopotent stem cell.
37. The selectable transgenic stem cell of Claim 35, wherein said stem cell is a spermatogonial, embryonic, osteogenic, hematopoietic, granulopoietic, sympathoadrenal, mesenchymal, epidermal, neuronal, neural crest, 0-2A progenitor, brain, kidney, pancreatic, liver or cardiac stem cell.
38. The selectable transgenic stem cell of Claim 35, wherein said stem cell is a selectable transgenic male germ cell.
39. A transgenic non-human vertebrate comprising the stem cell of Claim 35.
40. The transgenic non-human vertebrate of Claim 39, wherein said vertebrate is a non human mammal or a bird.
41. Vertebrate semen comprising a maturing male gamete obtained by the method of Claim 32.
42. A method of producing a non-human transgenic vertebrate animal line having native germ cells, comprising breeding of the vertebrate of Claim 39 with a member of the opposite sex of the same species; and selecting progeny for stem cell-specific expression of a xenogeneic fluorescent or light emitting protein.
43. A method of obtaining a selectable transgenic stem cell of a vertebrate, comprising: 62 WO 00/29602 PCT/US99/08277 administering to a gonad of a male vertebrate a transfection mixture comprising at least one transfecting agent and at least one polynucleotide comprising a transcriptional unit of a cyclin Al promoter sequence operatively linked to a DNA encoding a fluorescent or light-emitting protein, under conditions effective to reach a germ cell or germ cell precursor of the male vertebrate; and causing said polynucleotide to be taken up by, and released into, said germ cell or precursor cell; incorporating said polynucleotide into the genome of said germ cell or precursor cell; allowing said germ cell or precursor cell to develop into a maturing male gamete; and breeding said male vertebrate with a female of its species to obtain a transgenic progeny expressing said fluorescent or light-emitting protein in at least one of its stem cells, whereby said stem cell can be isolated or selected from a non-stem cell.
44. The method of Claim 43, wherein breeding is by in vitro or in vivo fertilization of an ovum of said female.
45. The method of Claim 43, wherein said cyclin Al promoter sequence comprises SEQ. ID. NO.:2, or an operative fragment or non-human homologue thereof, or an operative derivative of any of these.
46. The method of Claim 43, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit, whereby methylation in vivo of said promoter sequence is substantially prevented.
47. The method of Claim 46, wherein at least one of said insulator element(s) is a chicken P-globin insulator element.
48. The method of Claim 43, wherein said fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase or apoaequorin.
49. The method of Claim 43, wherein said vertebrate is a mammal or bird. 63 WO 00/29602 PCT/US99/08277
50. The method of Claim 43, wherein said vertebrate is a human, non-human primate, mouse, rat, rabbit, gerbil, hamster, canine, feline, ovine, bovine, swine, pachyderm, equine, or a farm or marine mammal.
51. The method of Claim 43, wherein said vertebrate is a duck, chicken, goose, ostrich, emu, dove, quail, guinea fowl, or turkey.
52. The method of Claim 43, wherein a stem cell of said transgenic progeny is grown in vitro.
53. The method of Claim 52, wherein said stem cell is grown in the presence of an inhibitor of DNA methylation.
54. A selectable transgenic stem cell obtained by the method of Claim 43.
55. The selectable transgenic stem cell of Claim 54, wherein said stem cell is a pluripotent, multipotent, bipotent, or monopotent stem cell.
56. The selectable transgenic stem cell of Claim 54, wherein said stem cell is a spermatogonial, embryonic, osteogenic, hematopoietic, granulopoietic, sympathoadrenal, mesenchymal, epidermal, neuronal, neural crest, O-2A progenitor, brain, kidney, pancreatic, liver or cardiac stem cell.
57. The selectable transgenic stem cell of Claim 54, wherein said stem cell is a selectable transgenic female or male germ cell.
58. A transgenic non-human vertebrate comprising the stem cell of Claim 54.
59. The transgenic non-human vertebrate of Claim 58, wherein said vertebrate is a non human mammal or a bird.
60. A maturing male gamete obtained by the method of Claim 43.
61. Vertebrate semen comprising the maturing male gamete of Claim 60. 64 WO 00/29602 PCTIUS99/08277
62. A method of producing a non-human transgenic vertebrate animal line having native germ cells, comprising breeding the vertebrate of Claim 58 with a member of the opposite sex of the same species; and selecting progeny for stem cell-specific expression of a xenogeneic fluorescent or light emitting protein.
63. A method of obtaining a selectable stem cell, comprising: obtaining a maturing male germ cell from a vertebrate; transfecting said male germ cell in vitro with at least one polynucleotide comprising a transcriptional unit of a stem cell-specific promoter operatively linked to a DNA encoding a fluorescent or light-emitting protein, in the presence of a gene delivery mixture comprising at least one transfecting agent, at about or below the vertebrate's body temperature and for a transfection effective period of time; causing said polynucleotide to be taken up by, and released into said germ cell; and fertilizing an ovum with said germ cell such that a transgenic progeny expressing said fluorescent or light-emitting protein in at least one of its stem cells is obtained, said stem cell(s) being selectable from non-stem cells by detecting light emissions from said stem cell(s).
64. The method of Claim 63, wherein fertilizing an ovum is by in vitro or in vivo fertilization.
65. The method of Claim 63, wherein said stem cell-specific promoter is a cyclin Al promoter.
66. The method of Claim 63, wherein said cyclin Al promoter sequence comprises SEQ. ID. NO.:2, or an operative fragment or non-human homologue thereof, or an operative derivative of any of these.
67. The method of Claim 63, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit, whereby methylation in vivo of said promoter sequence is substantially prevented. 65 WO 00/29602 PCT/US99/08277
68. The method of Claim 67, wherein at least one of said insulator element(s) is a chicken p-globin insulator element.
69. The method of Claim 63, wherein said fluorescent protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaequorn.
70. The method of Claim 63, wherein said vertebrate is a mammal or bird.
71. The method of Claim 63, wherein said vertebrate is a human, non-human primate, mouse, rat, rabbit, gerbil, hamster, canine, feline, ovine, bovine, swine, pachyderm, equine, or a farm or marine mammal.
72. The method of Claim 63, wherein said vertebrate is a duck, chicken, goose, ostrich, emu, dove, quail, guinea fowl, or turkey.
73. The method of Claim 63, wherein a stem cell of said transgenic progeny is grown in vitro.
74. The method of Claim 73, wherein said stem cell is grown in the presence of an inhibitor of DNA methylation.
75. A selectable transgenic stem cell obtained by the method of Claim 63.
76. The selectable transgenic stem cell of Claim 75, wherein said stem cell is a pluripotent, multipotent, bipotent, or monopotent stem cell.
77. The selectable transgenic stem cell of Claim 75, wherein said stem cell is a spermatogonial, embryonic, osteogenic, hematopoietic, granulopoietic, sympathoadrenal, mesenchymal, epidermal, neuronal, neural crest, O-2A progenitor, brain, kidney, pancreatic, liver or cardiac stem cell.
78. The selectable transgenic stem cell of Claim 75, wherein said stem cell is a selectable transgenic female or male germ cell. 66 WO 00/29602 PCT/US99/08277
79. A transgenic non-human vertebrate comprising the selectable transgenic stem cell of Claim 75.
80. The transgenic non-human vertebrate of Claim 79, wherein said vertebrate is a non human mammal or a bird.
81. Vertebrate semen comprising the male germ cell of Claim 78.
82. A method of producing a non-human transgenic vertebrate animal line having native germ cells, comprising breeding the vertebrate of Claim 79 with a member of the opposite sex of the same species; and selecting progeny for stem cell-specific expression of a xenogeneic fluorescent or light emitting protein.
83. A method of obtaining a selectable stem cell, comprising: obtaining a maturing male germ cell from a vertebrate; transfecting said male germ cell in vitro with at least one polynucleotide comprising a transcriptional unit of a cyclin A l promoter operatively linked to a DNA encoding a fluorescent or light-emitting protein, in the presence of a gene delivery mixture comprising at least one transfecting agent, at about or below the vertebrate's body temperature and for a transfection-effective period of time; and allowing said polynucleotide to be taken up by, and released into said germ cell; fertilizing an ovum with said germ cell such that a transgenic progeny expressing said fluorescent or light-emitting protein in at least one of its stem cells is obtained, said stem cell(s) being selectable from non-stem cells by detecting light emissions from said stem cell(s).
84. The method of Claim 83, wherein fertilizing an ovum is by in vitro or in vivo fertilization.
85. The method of Claim 83, wherein said cyclin Al promoter sequence comprises SEQ. ID. NO.:2, or an operative fragment or non-human homologue thereof, or an operative derivative of any of these. 67 WO 00/29602 PCT/US99/08277
86. The method of Claim 83, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit, whereby methylation in vivo of said promoter sequence is substantially prevented.
87. The method of Claim 86, wherein at least one of said insulator element(s) is a chicken p-globin insulator element.
88. The method of Claim 83, wherein said fluorescent protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaequorin.
89. The method of Claim 83, wherein said vertebrate is a mammal or bird.
90. The method of Claim 83, wherein said vertebrate is a human, non-human primate, mouse, rat, rabbit, gerbil, hamster, canine, feline, ovine, bovine, swine, pachyderm, equine, or a farm or marine mammal.
91. The method of Claim 83, wherein said vertebrate is a duck, chicken, goose, ostrich, emu, dove, quail, guinea fowl, or turkey.
92. The method of Claim 83, wherein a stem cell of said transgenic progeny is grown in vitro.
93. The method of Claim 92, wherein said stem cell is grown in the presence of an inhibitor of DNA methylation.
94. A selectable transgenic stem cell obtained by the method of Claim 83.
95. The selectable transgenic stem cell of Claim 94, wherein said stem cell is a pluripotent, multipotent, bipotent, or monopotent stem cell.
96. The selectable transgenic stem cell of Claim 94, wherein said stem cell is a spermatogonial, embryonic, osteogenic, hematopoietic, granulopoietic, sympathoadrenal, 68 WO 00/29602 PCTIUS99/08277 mesenchymal, epidermal, neuronal, neural crest, O-2A progenitor, brain, kidney, pancreatic, liver or cardiac stem cell.
97. The selectable transgenic stem cell of Claim 94, wherein said stem cell is a selectable transgenic female or male germ cell.
98. A transgenic non-human vertebrate comprising the stem cell of Claim 94.
99. The transgenic non-human vertebrate of Claim 98, wherein said vertebrate is a non human mammal or a bird.
100. Vertebrate semen comprising the male germ cell of Claim 97.
101. A method of producing a non-human transgenic vertebrate animal line having native germ cells, comprising breeding of the vertebrate of Claim 98 with a member of the opposite sex of the same species; and selecting progeny for stem cell-specific expression of a xenogeneic fluorescent or light-emitting protein.
102. A nucleic acid construct, comprising a cyclin Al promoter having nucleotide sequence (SEQ. ID. NO.:2), or an operative fragment or non-human homologue thereof, or an operative derivative of any of these.
103. The nucleic acid construct of Claim 102, further comprising said cyclin Al promoter operatively linked to a nucleotide sequence encoding a fluorescent or light-emitting protein, as a transcriptional unit.
104. The nucleic acid construct of Claim 103, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit.
105. The nucleic acid construct of Claim 104, wherein at least one of said insulator element(s) is a chicken P-globin insulator element. 69 WO 00/29602 PCTIUS99/08277
106. The nucleic acid construct of Claim 103, wherein the encoded fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaequorin.
107. A transgenic vertebrate cell containing the nucleic acid construct of Claim 102.
108. A transgenic non-human vertebrate comprising the cell of Claim 107.
109. The transgenic non-human vertebrate of Claim 108, wherein said vertebrate is a non human mammal or a bird.
110. The transgenic vertebrate cell of Claim 107, wherein said cell is a transgenic stem cell.
111. The transgenic stem cell of Claim 110, wherein said stem cell is a pluripotent, multipotent, bipotent, or monopotent stem cell.
112. The transgenic stem cell of Claim 110, wherein said stem cell is a spermatogonial, hematopoietic, embryonic, osteogenic, granulopoietic, sympathoadrenal, mesenchymal, epidermal, neuronal, neural crest, 0-2A progenitor, brain, kidney, pancreatic, liver or cardiac stem cell.
113. The transgenic stem cell of Claim 110, grown in vitro.
114. The transgenic stem cell of Claim 113, grown in the presence of an inhibitor of DNA methylation.
115. A transgenic non-human vertebrate comprising the transgenic stem cell of Claim 110.
116. The transgenic non-human vertebrate of Claim 115, wherein said vertebrate is a non-human primate, mouse, rat, rabbit, gerbil, hamster, canine, feline, ovine, bovine, swine, pachyderm, equine, or a farm or marine mammal. 70 WO 00/29602 PCT/US99/08277
117. The transgenic non-human vertebrate of Claim 115, wherein said vertebrate is a duck, chicken, goose, ostrich, emu, dove, quail, guinea fowl, or turkey.
118 A kit for transfecting a male vertebrate's germ cells, comprising: a transfecting agent and a polynucleotide comprising a transcriptional unit of a human cyclin Al promoter sequence having SEQ. ID. NO.:2, or an operative fragment or non-human homologue thereof, or an operative derivative of any of these, operatively linked to a DNA having a nucleotide sequence encoding a fluorescent or light-emitting protein, whereby said kit may be used to transfect said germ cells.
119. The kit of Claim 118, wherein the transfecting agent is a liposome, viral vector, transferrin-polylysine enhanced viral vector, retroviral vector, lentiviral vector, or uptake enhancing DNA segment, or a mixture of any of these.
120. The kit of Claim 118, wherein the transfecting agent comprises a retroviral vector, adenoviral vector, transferrin-polylysine enhanced adenoviral vector, human immunodeficiency virus vector, lentiviral vector, Moloney murine leukemia virus-derived vector, mumps vector, a DNA segment that facilitates polynucleotide uptake by and release into the cytoplasm of germ cells, or comprises an operative fragment of- or mixture of any of these.
121. The kit of Claim 118, wherein the transfecting agent comprises an adenovirus vector having endosomal lytic activity, and the polynucleotide is operatively linked to the vector.
122. The kit of Claim 118, wherein the transfecting agent comprises a lipid transfecting agent.
123. The kit of Claim 118, wherein the transfecting agent further comprises a male-germ-cell-targeting molecule.
124. The kit of Claim 123, wherein the male-germ-cell-targeting molecule is specific for targeting spermatogonia and comprises a c-kit ligand.
125. The kit of Claim 118, further comprising an immunosuppressing agent. 71 WO 00/29602 PCT/US99/08277
126. The kit of Claim 125, wherein the immunosuppressing agent is cyclosporin or a corticosteroid.
127. The kit of Claim 123, wherein the kit contains at least one additional polynucleotide comprising a nucleotide sequence encoding for expression of a desired trait.
128. The kit of Claim 127, wherein the male-germ-cell-targeting molecule is specifically targeted to spermatogonia and comprises a c-kit ligand; and the kit contains at least one additional polynucleotide comprising a nucleotide sequence encoding for expression of a desired trait.
129. The kit of Claim 123, wherein the male-germ-cell-targeting molecule is specifically targeted to spermatogonia and comprises a c-kit ligand; and the DNA having a nucleotide sequence encoding a fluorescent protein is operatively linked to a cyclin Al promoter, c-kit promoter, B-Myb promoter, c-raf-1 promoter, ATM (ataxia telangiectasia) promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC-1 promoter, HSP 90 (heat shock gene) promoter, or FRMI (from fragile X site) promoter.
130. The kit of Claim 118, wherein said polynucleotide further comprises at least one insulator element flanking said transcriptional unit.
131. The kit of Claim 130, wherein at least one of said insulator element(s) is a chicken P-globin insulator element.
132. The kit of Claim 118, wherein said fluorescent or light-emitting protein is a green fluorescent protein, yellow fluorescent protein, blue fluorescent protein, phycobiliprotein, luciferase, or apoaequorn. 72
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09191920 | 1998-11-13 | ||
WOUS9824238 | 1998-11-13 | ||
US09/191,920 US6316692B1 (en) | 1997-11-14 | 1998-11-13 | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies |
PCT/US1998/024238 WO1999025863A1 (en) | 1997-11-14 | 1998-11-13 | Transfection and transfer of male germ cells for generation of transgenic species |
PCT/US1999/008277 WO2000029602A1 (en) | 1998-11-13 | 1999-04-15 | Transfection of male germ cells for generation of selectable transgenic stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3563499A true AU3563499A (en) | 2000-06-05 |
Family
ID=26794482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU35634/99A Abandoned AU3563499A (en) | 1998-11-13 | 1999-04-15 | Transfection of male germ cells for generation of selectable transgenic stem cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1129205A1 (en) |
JP (1) | JP2003526326A (en) |
AU (1) | AU3563499A (en) |
CA (1) | CA2350829A1 (en) |
WO (1) | WO2000029602A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU781014B2 (en) * | 1999-05-13 | 2005-04-28 | Cedars-Sinai Medical Center | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696404B2 (en) | 1996-08-19 | 2010-04-13 | Advanced Cell Technology, Inc. | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
US7294755B1 (en) | 1997-11-14 | 2007-11-13 | Cedars-Sinai Medical Center | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
EP1159404A2 (en) * | 1999-03-02 | 2001-12-05 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US7053187B2 (en) * | 2000-03-28 | 2006-05-30 | Gioagri Corporation | Sperm-specific monoclonal antibody, mAbC |
KR100569168B1 (en) * | 2003-08-08 | 2006-04-07 | (주)아비코아생명공학연구소 | Method for Culturing Avian Spermatogonial Stem Cells and Avian Spermatogonial Stem Cells Prepared thereby |
GB0325140D0 (en) * | 2003-10-28 | 2003-12-03 | Babraham Inst | Methods for selecting gametes and for producing genetically modified non-human animals |
US20140359795A1 (en) * | 2013-05-31 | 2014-12-04 | Recombinetics, Inc. | Genetic techniques for making animals with sortable sperm |
US9681615B2 (en) | 2013-06-20 | 2017-06-20 | Elwha Llc | Rapid breeding of plants |
US20140378755A1 (en) * | 2013-06-20 | 2014-12-25 | Elwha Llc | Rapid breeding of animals |
CN105900922A (en) * | 2016-04-25 | 2016-08-31 | 固镇县益民养殖专业合作社 | Breeding method for healthcare tea chickens |
CN111838071B (en) * | 2020-08-07 | 2022-05-03 | 江苏省家禽科学研究所 | Method for breeding pigeons with black tail and/or phoenix head characters |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1228210B (en) * | 1989-01-10 | 1991-06-05 | Consiglio Nazionale Ricerche | PROCEDURE FOR THE INTRODUCTION OF EXOGENOUS DNA INTO SOMATIC AND GERMINAL CELLS OF ANIMALS. |
US20030125519A1 (en) * | 1990-08-27 | 2003-07-03 | Peter Besmer | Ligand for the c-kit receptor and methods of use thereof |
JPH0591829A (en) * | 1991-09-27 | 1993-04-16 | N T Sci:Kk | Transgenic animal by gene transduction of enzyme catalyzing bioluminescence |
CA2125161A1 (en) * | 1991-12-06 | 1993-06-10 | Ralph L. Brinster | Repopulation of testicular seminiferous tubules with foreign cells, corresponding resultant germ cells, and corresponding resultant animals and progeny |
WO1994023046A1 (en) * | 1993-04-07 | 1994-10-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
WO1995002041A1 (en) * | 1993-07-09 | 1995-01-19 | La Jolla Cancer Research Foundation | Conditionally immortalized germ cell lines |
JPH10304790A (en) * | 1995-09-29 | 1998-11-17 | Hoechst Japan Ltd | Formation of transgenic animal |
JPH09220039A (en) * | 1996-02-14 | 1997-08-26 | Chihiro Koike | Method for introducing external gene into sperm or ovum and producing method for transgenic animal |
AU6555398A (en) * | 1997-03-13 | 1998-09-29 | Vanderbilt University | Methods of constructing a gene mutation library and compounds and compositions thereof |
-
1999
- 1999-04-15 WO PCT/US1999/008277 patent/WO2000029602A1/en not_active Application Discontinuation
- 1999-04-15 JP JP2000582583A patent/JP2003526326A/en active Pending
- 1999-04-15 EP EP99917539A patent/EP1129205A1/en not_active Withdrawn
- 1999-04-15 AU AU35634/99A patent/AU3563499A/en not_active Abandoned
- 1999-04-15 CA CA002350829A patent/CA2350829A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU781014B2 (en) * | 1999-05-13 | 2005-04-28 | Cedars-Sinai Medical Center | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
Also Published As
Publication number | Publication date |
---|---|
JP2003526326A (en) | 2003-09-09 |
EP1129205A1 (en) | 2001-09-05 |
WO2000029602A1 (en) | 2000-05-25 |
CA2350829A1 (en) | 2000-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU761758B2 (en) | Transfection and transfer of male germ cells for generation of transgenic species | |
US20200017882A1 (en) | Engineering of humanized car t-cell and platelets by genetic complementation | |
US20020056148A1 (en) | Transfection, storage and transfer of male germ cells for generation of selectable transgenic stem cells | |
AU3563499A (en) | Transfection of male germ cells for generation of selectable transgenic stem cells | |
US20080178311A1 (en) | Transfection, storage and transfer of male germ cells for generation of transgenic species & genetic therapies | |
JP2022522848A (en) | Genome-edited bird | |
AU781014B2 (en) | Genetic modification of male germ cells for generation of transgenic species and genetic therapies | |
WO2000029601A1 (en) | A method for depopulating of vertebrate testis and for generation of transgenic species | |
Wang et al. | Progress toward the culture and transformation of chicken blastodermal cells | |
US6734338B1 (en) | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies | |
US20050034177A1 (en) | Genetic modification of male germ cells for generation of transgenic species & genetic therapies | |
US7435591B2 (en) | Compositions and methods for increasing animal size growth rate | |
WO1997038091A1 (en) | METHODS FOR ENHANCING ANIMAL GROWTH AND CELL PROLIFERATION BY ELIMINATION OF FUNCTIONAL p27?Kip1¿ | |
US20030027777A1 (en) | Methods for enhancing animal growth and cell proliferation by elimination of the cyclin-dependent kinase inhibitor function of p27Kip1 | |
Khatun | Identification of gonial stem cells and Leydig cells in transgenic medaka (Oryzias latipes) reporter strains | |
Perkins | Further characterization of the murine embryonic lethal mutation, H beta 58, and its role in the visceral yolk sac | |
Kim | Modeling human prostate cancer development using transgenic mice with heterogeneous mutations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |